

Curriculum Vitae
Lisa Anne Bero, PhD

Title and Affiliation
(as of July 1, 2020)

Research Professor

School of Medicine (General Internal Medicine)

Chief Scientist

Center for Bioethics and Humanities

The University of Colorado CU Anschutz Medical Center

Denver, Colorado

lisa.bero@cuanschutz.edu

Honorary Professor

Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health

Sydney Health Ethics

Sydney Initiative for Truth

The University of Sydney

Fellow, Collegium Ramazzini

Education

- | | |
|---------|---|
| 1988-90 | Pew Foundation Postdoctoral Fellowship
Health Policy
University of California, San Francisco, California |
| 1988 | Clinical Epidemiology Research Methods
Epidemiology (Certificate)
University of California, San Francisco, California |
| 1989 | Workshop on Teaching
Education (Certificate)
University of California, San Francisco, California |
| 1987-88 | NIDA Postdoctoral Fellowship, Pharmacology
Department of Pharmacology
University of California, San Francisco, California |
| 1987 | Doctor of Philosophy, Pharmacology
Department of Pharmacology and Toxicology
Duke University
Durham, North Carolina |
| 1980 | Bachelor of Science, Physiology/Philosophy
Michigan State University
(Honors College)
East Lansing, Michigan |

Specialty/Subspecialty

Academic – industry relations / Commercial determinants of health
Pharmaceutical policy
Tobacco control policy
Environmental risk assessment
Nutrition
Evidence-based health care
Meta-analysis, systematic review, and evidence synthesis methods

Other Academic Positions Held

Jan 2019-
Jan 2020 Associate Dean / Academic Lead - Research
Faculty of Medicine and Health, School of Pharmacy

July 2000-
August 2014 Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco

July 2000-
August 2014 Core Faculty, Professor level
Institute for Health Policy Studies
School of Medicine
University of California, San Francisco

July 2000-
Jan 2013 Vice Chair, Research
Department of Clinical Pharmacy
University of California, San Francisco

July 1996-
June 2000 Associate Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco

July 1996-
June 2000 Core Faculty, Associate level
Institute for Health Policy Studies
School of Medicine
University of California, San Francisco

July 1995-
June 1996 Assistant Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco

July 1995-
June 1996 Core Faculty, Assistant Professor level
Institute for Health Policy Studies
School of Medicine
University of California, San Francisco

July 1990-
June 1995 Assistant Adjunct Professor
Division of Clinical Pharmacy
School of Pharmacy

University of California, San Francisco

July 1990-
June 1995 Core Faculty, Assistant Adjunct level
Institute for Health Policy Studies
School of Medicine
University of California, San Francisco

July 1988-
June 1990 Pew Foundation Postdoctoral Fellow, Health Policy
Institute for Health Policy Studies
School of Medicine
University of California, San Francisco

July 1987
June 1998 NIDA Postdoctoral Fellow, Pharmacology
Department of Pharmacology
University of California, San Francisco

September 1981 Research Associate
August 1983 Department of Psychiatry
Duke University

September 1980 Graduate Research Assistant
August 1981 Department of Pharmacology and Toxicology
Michigan State University

Current Memberships: Professional, Scientific and Scholarly Societies

The Cochrane Collaboration
American Public Health Association

Honors and Awards

- 2019 Hamilton Medal from Queen's University Belfast for Health Services Research to Change Public Policy
- 2017-onward Fellow, Collegium Ramazzini
- 2017 Research Australia, Data Innovation in Health and Medical Research Award, Highly Commended
- 2015 Anne Anderson Award, Cochrane Collaboration
- 2013 Bill Silverman Prize from The Cochrane Collaboration for the paper: Roseman, M, Turner, EH, Lexchin, J, Coyne, JC, **Bero, LA**, Thombs, BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ 2012;**345**:e5155.
- 2011 Research Preceptor for 2013 CHIH Foundation Research Award to Harinder Chahal for "Availability and Pricing of Essential Medicines in Haiti"
- 2011 Research Preceptor for Gary Rifkind Spring Research Seminar Award to Angela Anson (student category) for "Prices, availability and affordability of the World Health Organization's Essential Medicines for children in Guatemala"

- 2011 Co-author for Gary Rifkind Spring Research Seminar Award to Donna Odierna (professional researcher/ assistant professor category) for “Arguments for and against the use of Systematic Reviews in Healthcare Decision Making: *Cui Bono?*”
- 2010 Research Preceptor for 2010 CHIH Foundation Research Award to Timothy Millar and Shirley Wong for “Comparison of the World Health Organization Essential Medicines List (EML) with United States Medicaid Preferred Drug Lists (PDLs)”
- 2009 UCSF Distinction in Mentoring Award
- 2009 Harold S. Luft Award for Mentoring in Health Services and Health Policy Research
- 2009 Research Preceptor for Gary Rifkind Spring Research Seminar Award to Luke Tso (student category) for “Student Pharmacist Exposure and Attitudes towards Pharmaceutical Company Marketing Practices”
- 2008 Nominated for UCSF Lifetime Achievement in Mentoring Award
- 2007 Nominated for UCSF Lifetime Achievement in Mentoring Award
- 2004,2006 Author of most cited paper in *Tobacco Control* for 3 months
- 2003 Author of most cited paper in *Public Money and Management*
- 1999 Department of Clinical Pharmacy STAR award for mentoring
- 1998 Special consultant to the World Bank for a report on Tobacco Control Policies in Developing Countries
- 1998, 1999, 2003, 2004, 2005, 2006 Nominated for Chancellor's Award for the Advancement of Women (6 times)
- 1998 LaBelle Lectureship Award from McMaster University, Canada
- 1997 Award for best article published in 1996 in the *International Journal of Technology Assessment in Health Care*
- 1994-1996 Special Consultant to the European Union Committee on Technology Assessment, Subgroup on Dissemination and Impact
- 1991-1993 Special Advisor to World Health Organization
- 1991 Regents' Honor Roll for Community Service, University of California, San Francisco

TEACHING

(* 1/2002 through 9/30/2002 Sabbatical)

(* 9/2009 through 3 / 2010 Sabbatical at the World Health Organization, Department of Essential Medicines and Pharmaceutical Policy)

The University of Colorado

2024 Guest Lecturer, Research Integrity (RCR) course. “Conflicts of Interest and Research”

2024 Guest Lecturer, HSMP 6617, Interpreting Health Policy and Management Research, “Evidence Synthesis”

2021,22 Guest Lecturer, EHOH 6617, Environmental and Occupational Health, Industry influence on the design, conduct and dissemination of research

2021,22 Guest Lecturer, HSMP 6617, Interpreting Health Policy and Management Research, The role of systematic reviews in policy.

2021 Nutrition Seminar Series, “Breaking the Cycle of Bias: Corporate influence on nutrition research and guidelines, Feb 4

2021 Guest Lecturer, Cannabis Research and Policy Project, Systematic and Scoping reviews, several sessions

The University of Sydney

2015-2019 Unit of Study Director, Research Methods, for Masters students (PHAR6000), Semester 1

2017 Unit of Study Director, Research Methods, for honours students (PHAR4815), Semester 1

2016-2020 Charles Perkins Centre Multidisciplinary Course “Evidence Synthesis for Everyone”

2015-2020 Guest lecturer, Clinical Epidemiology Methods

Other Teaching Activities

2017-2020 Workshops for Consumer Organizations, Conflicts of Interest in Medical Research and Education (with Ray Moynihan), 4 -5 workshops per year across Australia

2015 Workshop for Journalists “Spotting conflicts of interest in research” Sydney

2012 Invited faculty for “Fourteenth Rocky Mountain Workshop on Evidence-Based Medicine.” Steamboat Springs, Colorado (July 21- July 26)

2011 Tutorial on the Cochrane Handbook for Conducting Systematic Reviews. 10 weeks, Winter quarter, 2 hours per week. Attended by 23 students, residents, faculty from Schools of Pharmacy, Medicine and Nursing, UCSF.

- 2010,11 “The rules, the ethics, and the thorny issues of publication.” Tobacco Control Research Seminar Series (Oct 5, 2011; November 8, 2011)
- 2011 Invited faculty for “Thirteenth Rocky Mountain Workshop on Evidence-Based Medicine.” Vail, Colorado (July 16 – July 21)
- 2009 Invited faculty for “Eleventh Rocky Mountain Workshop on Evidence-Based Medicine.” Vail, Colorado (July 26 – July 30)
- 2008 Invited faculty for “Tenth Rocky Mountain Workshop on Evidence-Based Medicine.” Midway, Utah (July 27 – July 31)
- 2008 Invited speaker. “Ethical conduct in industry/academia research collaborations.” Biomechanical Testing Facility's Professional Development Workshop Series, SFGH (July 21)
- 2008 Invited speaker. “Systematic reviews, meta-analysis and the Cochrane Collaboration.” Division of General Pediatrics, UCSF Fellowship Seminar (July 16).
- 2008 Invited speaker. “Effects of Pharmaceutical Industry Marketing.” UCSF Integrative Medicine Forum. (June 28)
- 2007 Co-Chair, lecturer and small group facilitator for UCSF CME course “Marketing of Medicines” (November 3)
- 2007 UC Berkeley PH223B: Cases in Health Management: Evidence-based Health Services Management. Invited speaker, “Observations on Evidence-Based Medicine” (October 3)
- 2007 “Establishing an Independent Research Program.” Speaker at Faculty Welcome Week (September 11)
- 2007 Introduction to Tobacco Control Research.” Center for Tobacco Control Research and Education, Lecture and discussion (August 22)
- 2007 Invited faculty for “Ninth Rocky Mountain Workshop on Evidence-Based Medicine.” Colorado Springs, Colorado (August 4 – August 9)
- 2006 “Raising children in the Bay Area: Faculty Perspective.” Speaker at Faculty Welcome Week (September 19)
- 2006 Invited faculty for “Eighth Rocky Mountain Workshop on Evidence-Based Medicine.” Keystone, Colorado (August 6 – August 10)
- 2006 “All you Ever Wanted to Know About Tobacco Control.” Center for Tobacco Control Research and Education, Lecture and discussion (August 23)
- 2006 “Dental Methods.” School of Dentistry, Lecture and discussion (August 30)
- 2006 “Conflicts of Interests Issues in Stem Cell Research.” Ethical Worlds of Stem Cell Medicine, Lecture (September 29)
- 2006 “Scientific Methods.” School of Dentistry, Lecture and discussion (November 22)

- 2005 Invited faculty for “Seventh Rocky Mountain Workshop on Evidence-Based Medicine.” Keystone, Colorado (July 31 – August 4)
- 2005 “All you ever Wanted to Know About Tobacco Control.” Center for Tobacco Control Research and Education, Lecture and discussion (October 5)
- 2004 “Meta-analysis and the Cochrane Collaboration.” CE Fellowship in Clinical Literature Access, Analysis and Evaluation, Lecture (July 26)
- 2004 “All you Ever Wanted to Know About Tobacco Control.” Center for Tobacco Control Research and Education, Lecture and discussion (September 23)
- 2003 “The Cochrane Collaboration.” Videoconference lecture for UCSD Pharmacy Students, (May 7)
- 2003 “All you Ever Wanted to Know About Tobacco Control.” Center for Tobacco Control Research and Education, Lecture and discussion (March 19)
- 2003 Invited faculty for “Fifth Rocky Mountain Workshop on Evidence-Based Medicine.” Keystone, Colorado (August 1-6)
- 2002 Invited faculty for “Fourth Rocky Mountain Workshop on Evidence-Based Medicine.” Keystone, Colorado (August 11-15)
- 2001 Invited faculty for “Third Rocky Mountain Workshop on Evidence-Based Medicine.” Keystone, Colorado (August 5-9)
- 2000 Invited faculty for “Second Rocky Mountain Workshop on Evidence-Based Medicine.” Vail, Colorado (August 6-10)
- 1999 Invited faculty for “First Rocky Mountain Workshop on Evidence-Based Medicine.” Vail, Colorado (August 1 - 5)
- 1999 “The Cochrane Collaboration Effective Practice and Organization of Care Effort: Using Reviews to Change Behavior.” IHPS Health Policy Seminar, UCSF (March 22)
- 1996 “Meta-analysis and the Cochrane Collaboration.” for the Outcomes Research and Clinical Epidemiology Training Program, University of California, San Francisco (August 9)
- 1995 “Meta-analysis: Epidemiologic Issues.” for the Epidemiology Clinical Research Training Program, University of California, San Francisco (February 21)
- 1991-1993 Advisor to World Health Organization: to draft and field test the “Guide to Good Prescribing” – a problem-based module for teaching clinical pharmacology. University of California, San Francisco was one of 7 sites selected for the field test among UCSF medical students. Field test completed Spring 1992
- 1987 –1995 Lecturer in departments of Pharmacology, Clinical Pharmacy, Pharmaceutical Chemistry. Subjects: neuropharmacology, developmental pharmacology, chemistry of

opioids, geriatric pharmacology, health policy aspects of geriatric pharmacy, policy aspects of liability for drug-induced injury.
University of California San Francisco

1984-86 Pharmacology Tutor for medical students, Duke University

The University of California, San Francisco

1999-2013 Course Coordinator, “Study Design Evaluation”

1987-2013 Lecturer in various courses on meta-analysis, critical appraisal, translating research into policy, and managing conflicts of interest

Institute for Health Policy Studies, Teaching

2006 “When is Research Research or Marketing or Advocacy,” for the Institute for Health Policy Studies (November 6)

2005 “How to keep the Job you Always Wanted,” for the Institute for Health Policy Studies Health Policy Seminar Series (June 6)

2003 “Conflicts of Interest and Clinical Trials,” for the Institute for Health Policy Studies Health Policy Seminar Series (May 5)

2000 “Globalization and the Cochrane Collaboration,” Globalization of Health Care course (February 7)

1994 “Order out of Chaos: Conducting Structured Reviews of the Medical Literature,” for the Institute for Health Policy Studies Health Policy Seminar Series (October 31)

1993-now Seminar: “How To Get Your Paper Published Quickly” (with Drummond Rennie until 2000) for Institute for Health Policy Studies Postdoctoral Fellows, Fall or Winter Quarter, annually

1992-1998 Course taught: “Translating Research into Policy” for Institute for Health Policy Studies Postdoctoral Fellows, Spring Quarter, alternate years

1992-1997 Academic Coordinator for Institute for Health Policy Studies Postdoctoral Fellowship Program

1991–now Advisor for Health Policy Postdoctoral Fellows, Institute for Health Policy Studies

1989–1997 Coordinator for Health Policy Seminars for Postdoctoral Fellows, Institute for Health Policy Studies (year-round)

Residents and Fellows Supervised

CoSPH Public Health Capstone and Masters: Jeane-Pierre Oberste
PhD students

2018- Sally McDonald

2017- 2021	Kellia Chiu (PhD completed)
2016-2020	Zhicheng (Jeff) Wang (PhD completed)
2015-2017	Alice Fabbri (PhD completed)
2015-2019	Nicholas Chartres (PhD completed)
<u>Masters students</u>	
2016-2017	Sally McDonald (MS completed)
<u>Fellows</u>	
2018-2020	Joy Dai-Keller, PhD. Postdoctoral Fellow
2018-2020	Cynthia Kroeger, PhD. Postdoctoral Fellow
2018-2019	Emily Karanges, PhD. Postdoctoral Fellow
2017-2020	Lisa Parker, PhD. Postdoctoral Fellow
2017-2018	Jane Williams, Ph.D. Postdoctoral Fellow
2015-2018	Quinn Grundy, PhD. Postdoctoral Fellow
2013	Jeppe Schroll, doctoral student, University of Copenhagen, 3-month visiting Cochrane fellow
2012	Francisca Sureda Lull, Dr.PH. Cancer Prevention and Control Visiting Fellow, Barcelona, Spain
2010-2011	Ansgar Gerhardas, MD, MA, MPH. Harkness Fellow
2010-2011	Beth Hart, MD, medical student. Doris Duke Fellow
2010	Andreas Lundh, doctoral student, University of Copenhagen, 3-month visiting fellow
2008-2010	Elena Lingas, Ph.D. – Center for Tobacco Control Research and Education Postdoctoral Research Fellow
2007-2009	Christopher Ganchoff, Ph.D. – Center for Tobacco Control Research and Education Postdoctoral Research Fellow
2007-2008	Donna Odierna, Dr. P.H. - Institute for Health Policy Postdoctoral Fellow
2006-2007	Kristin Rising, MD student – Doris Duke Fellow
2003-2007	Christopher Jewel, PhD - Institute for Health Policy Postdoctoral Fellow
2003-2006	Daniel Cook, PhD - Institute for Health Policy / Legacy Postdoctoral Fellow
2003-2006	Dorie Apollonio, PhD - Institute for Health Policy / Legacy Postdoctoral Fellow
2002-2005	Bonnie Glaser, PhD – Institute for Health Policy Postdoctoral Fellow
2001-2005	Joshua Dunsby, PhD – Institute for Health Policy / Legacy Postdoctoral Fellow
2001-2003	Shellie Kahane, MD, MPH – Institute for Health Policy Postdoctoral Fellow
1999-2001	Elizabeth Boyd, PhD - Institute for Health Policy Postdoctoral Fellow
1999	Mark Halladay, Harkness Fellow
1999	Sarah Youssof – UCSF Student Research Committee Summer Fellow
1999	Elizabeth Gruskin, PhD - Institute for Health Policy Postdoctoral Fellow
1998	Lee Ann Patterson - Institute for Health Policy Postdoctoral Fellow
1998-1999	Johnny Beney-Clinical Pharmacy and Institute for Health Policy Postdoctoral Fellow
1997-1999	Theresa Montini, PhD - Institute for Health Policy Postdoctoral Fellow
1995-1997	Ruth Malone, PhD - AHCPR and Pew Postdoctoral Fellow, IHPS
1992-1995	Mildred Cho, PhD – Pew Postdoctoral Fellow, IHPS
1993-1994	Daniel Stryer, MD, MPH - Department of Veterans Affairs Postdoctoral Fellow
1992	Ira Sharenow – Visiting Predoctoral Fellow
<u>Residents</u>	
2006	Veronica Yank, MD – Medicine Resident, University of Washington School of Medicine
1995-1996	Gina Ryan, PharmD - Clinical Pharmacy Resident, UCSF
1995-1996	Deepa Setty, PharmD - Clinical Pharmacy Resident, UCSF
1993-1994	Risa Vitanka, PharmD - Clinical Pharmacy Resident, UCSF

Other mentoring and advising activities

- 2017 Behrad Behdarvand – Pharmacy honours, University of Sydney
- 2016 Alexandra Lai - Pharmacy honours, University of Sydney
- 2015 Kellia Chiu – Pharmacy honours, University of Sydney
- 2014 Zhicheng Wang, Wing Sum Ng – Pharmacy honours, University of Sydney
- 2013- Research Preceptor for Health Policy Pathway student Jennifer Koehl
- 2013-2018 K Award Career Mentor for Veronica Yank, Stanford University
- 2012-2014 Research Preceptor for Health Policy Pathway students Tina Tran and Maher Abdel-Sattar
- 2012- Member of Dissertation Committee (Qualifying committee chair) for Guinn Grundy, Department of Social and Behavioral Sciences, UCSF
- 2011-2013 Research Preceptor for Clinical Pathway student Soniya Tambe
- 2011-2014 Member of Dissertation Committee for David Tuller, University of California, Berkeley
- 2010-2011 Member of Dissertation Committee for Anders Jorgensen, University of Copenhagen
- 2010-2011 Research Preceptor for Health Policy Pathway students Nicole Nguyen and Harinder Singh Chahal
- 2010-2015 K12 Mentor for Dorie Apollonio, UCSF
- 2009-2011 Research Preceptor for Health Policy Pathway student Angela Anson
- 2008-2010 Research Preceptor for Health Policy Pathway students Olga Mostovetsky, Tim Millar, Bryan Sandlund and Shirley Wong
- 2008 Chair, MD with Thesis Committee for Kristin Rising
- 2007-2009 K12 Mentor for Kirby Lee, Pharm.D.
- 2010- K mentor for Dorie Apollonio, Ph.D.
- 2007 Advisor for Nicholas Rasmussen, Ph.D., visiting professor on sabbatical from University of Sydney
- 2006-2008 Preceptor for Arnab Mukherjea, UC Berkeley, PhD candidate in Public Health. I was preceptor for his supplement to my TRDRP grant.
- 2006-2008 Member of dissertation committee for Nicole Wolfe, Ph.D. Social and Behavioral Sciences, UCSF
- 2006-2008 Research Preceptor for Health Policy and Management Pathway Students: Luke Tso and Olga Mostovetsky
- 2005-2007 Research Preceptor for Health Policy and Management Pathway Students: Gail Rattinger and Heather Houska
- 2005 Advisor for visiting scholar, Fieke Oostvogel, Masters in Biomedical Sciences, Leiden University, the Netherlands
- 2004-2005 Preceptor and Mentor for Health Policy and Management Pathway Students: Nancy Nguyen, Beatriz Bartase
- 2002-2006 PhD advisor (dissertation committee chair) for Martha Michel, Medical Informatics Program, UCSF
- 2003 Advisor for Tiffani Bright, minority student fellowship recipient (summer)
Faculty advisor for 2 Health Policy and Management Pathway students
Faculty speaker at mentoring dinner for women graduate students (June 10)
- 2001-2002 Faculty advisor for 1 Health Policy and Management Pathway student (during sabbatical)
- 2000-2001 Faculty advisor for 1 Health Policy and Management Pathway student

Teaching Awards

- 2016 Nominated for Supervisor of the Year at the University of Sydney.

- 2012, 2011 Dean’s Recognition of Teaching. Apple for Teachers Award, Winter.
2009, 2008
- 2009 UCSF Distinction in Mentoring Award
- 2009 Harold S. Luft Award for Mentoring in Health Services and Health Policy Research.

Dissemination of Teaching activities

Charles Perkins Centre, MOOC: *Easing the Burden of Obesity, Diabetes, and Cardiovascular Disease* <https://www.coursera.org/learn/easing-the-burden-of-obesity-diabetes-cvd/home/welcome>

In 2006-07, I received funding (See Grants and Awards) to develop a curriculum on the marketing practices of the pharmaceutical industry and disseminate it in open access materials, including podcasts, video and UCTV. This included development of a CME program on the marketing of medicine. The CME program was presented live and is available as an open-access web-based course launched in 2008. “Marketing of Medicines” is available for free at <https://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MED11006>. The lectures for this course area also available on YouTube.

My previously developed course, CP124 (Study Design Evaluation), has also been exported. The course has been translated into Spanish and is taught by Dr. Joaquin Barnoya at the Cardiovascular Unit of Guatemala (2005 – now).

PROFESSIONAL ACTIVITIES

Service to Professional, Scholarly, Scientific, Educational and Governmental Agencies and Organizations

- 2023-2024 Member, Organizing Committee for 8th World Conference on Research Integrity.
- 2020-now External Conflict of Interest Advisor for the Canadian Health Product and Food Branch (HPFB)'s future Nutrition Science Advisory Committee (NSAC), Cannabis Committees, and Pesticides Regulation Committee
- 2020-now Chair, Governance Committee, National Health and Medical Research Council (Australia)
- 2020-now Senior Editor, Research Integrity, Cochrane
- 2020 Search Committee Member for Clinical Professor in Evidence-Based Clinical Intervention Research, University of Southern Denmark
- 2018- now Senior Editor, Cochrane Public Health and Health Systems Network
- 2015-now Academic Editor, PLoS Biology, Meta-research section
- 2012 Search Committee Member for Professor of Clinical Pharmacy, University of Southern Denmark
- 2012 Proposal reviewer for Alliance for Health Policy and Systems Research (reviewed proposals for Health Policy and Systems Research in the field of Access to Medicines in low- and middle- income countries)
- 2011-2012 Consultant to National Institute for Environmental Health Sciences and National Toxicology Program. Advise on methods for systematic reviews and risk of bias assessment. Participated as speaker in series of 6 webinars re systematic reviews and risk of bias assessment (January – March 2012)
- 2011,2013 Chair, Anne Anderson Award Selection Committee, The Cochrane Collaboration
- 2007 Member of Ad Hoc Review Committee for Promotion to Associate Professor, Department of Public Health Sciences, University of Toronto.
- 2007 Member of Ad Hoc Review Committee for Promotion to Full Professor, Harvard University
- 2007 Member of Dissertation Committee for Barbara Mintzes, University of Toronto, Canada
- 1999-2003 Study Section member (Health Research and Dissemination Section), Agency for Health Care Research and Quality

Peer reviewer for the following granting agencies:

2002-now	Welcome Trust, UK
2001-now	National Institutes for Health (Ad hoc reviewer)
2000-now	Medical Research Council, UK
1999-now	Agency for Health Care Policy and Research Study Section on Health Research Implementation and Dissemination.
1996-2004	Robert Wood Johnson Foundation
1997-1998	UC Systemwide Biotechnology Research Program
1998-2005	National Science Foundation
1998-now	Canadian National Cancer Institute

Interviews for National lay media including newspapers, magazines, radio and television:

I am frequently interviewed for international and national lay media including newspapers, magazines, radio and television.

National Committees / Service

2022	Plenary speaker and workshop organizer, Sponsor Influence on Research, National Academies of Sciences, Engineering, and Medicine, Dec 14-16
2021-now	Chair, National Health and Medical Research Council Dietary Guidelines Governance Committee (Australia)
2020-2022	Chair, National Academy of Sciences Committee to Review EPA's IRIS Assessment Handbook
2020-now	Health Products and Food Branch External Conflict of Interest Advisor (Canada)
2016-now	Member, NHMRC Advisory Group on the Synthesis and Translation of Research Evidence (SToRE) (Australia)
2013-2017	Strategy Advisor, California Breast Cancer Prevention Initiative
2012-2014	Member, National Academy of Sciences Committee to Review the IRIS Process
2012	Member, National Toxicology Program (NTP) Board of Scientific Counselors (BSC) Working Group on Research Evidence Assessment Conclusions
2012	Conducted a focus group for NIH/Office of Research Integrity to gather research topics for future RFPs (March 15)
2010-2014	Reviewer for Agency for Health Care Research and Quality Evidence-Based Practice Center Reports

- 2009-2012 Member, Institute of Medicine Board on Health Care Services
- 2009-2011 Member, National Guideline Clearinghouse Editorial Advisory Board, ECRI Institute
- 2007- 2009 Member, Institute of Medicine Committee on Conflicts of Interest in Medical Research, Education and Practice
- 2007 Member, Institute of Medicine Roundtable on Evidence-Based Medicine. Sectorial Strategies Project
- 2004 Planning Committee, Institutional Conflict of Interest Conference, University of Nevada, Las Vegas
- 2002-04 Tobacco Funding Advisory Committee member, Joint Committee of National Cancer Institute and Legacy Foundation
- 2001-05 Advisory Board member, “Tobacco Deposition and Trial Testimony Archive” National Cancer Institute Project
- 2002 Advisory Board member, “Moral Issues and Human Rights in Tobacco Control” Rutgers University Research Project
- 1999-2001 Technical Expert Advisory Group member for Research Triangle Institute – group is working on “Systems to Rate the Strength of Scientific Evidence”
- 2000-2004 American Legacy Foundation Scientific and Advisory Panel on Policy
- 1997-2000 Ad Hoc Advisory Panel on Outcomes and Cost-Effectiveness, USP Drug Utilization Review Advisory Panel
- 1995 American Association of Colleges of Pharmacy, Graduate Education Committee

International Committees/ Service

- 2020-now Member, WHO Guideline Development Group for guideline on ensuring balanced national policies for access and safe use of controlled medicines
- 2020 Chair, Pharmaceutical Pricing Guideline Development Group, World Health Organization, February 26-28.
- 2019 Organizer for 2 workshops (Public Participation and Selection of Experts) for World Health Organization Science Division, Norms and Standards Department, June 17-28.
- 2018 Member, Advisory Group to recommend an update to the Preamble, International Agency for Research on Cancer (IARC), Lyon, France November 12-14
- 2015-now Member, Advisory Board for International Congress on Peer Review and Scientific Publication
- 2013-2017 Co-Chair, The Cochrane Collaboration Governing Board

- 2013,15 Chair, WHO [World Health Organization] Expert Committee on the Selection and Use of Essential Medicines
- 2011-2014 Member, WHO [World Health Organization] Guideline Review Committee
- 2011 Co-Chair, WHO [World Health Organization] Guideline Panel on Country Pharmaceutical Pricing Policies
- 2011 Chair, WHO [World Health Organization] Expert Committee on the Selection and Use of Essential Medicines
- 2011 Advisory Board for the Sixth International Congress on Peer Review in Biomedical Publication, Scientific Abstract Reviewer
- 2010 Chair, WHO [World Health Organization] Emergency Session of the Expert Committee on the Selection and Use of Essential Medicines
- 2010 Member, Who [World Health Organization] Committee on Rapid Advice Guideline on Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Viruses
- 2010 Chair, Abstract Committee for Cochrane Colloquium, Keystone Colorado (October)
- 2009 Member / Rapporteur, WHO [World Health Organization] Expert Committee on the Selection and Use of Essential Medicines
- 2008 Search Committee member for Editor in Chief for The Cochrane Library.
- 2008 Chair of priority Setting Grant Review Committee for Cochrane.
- 2008- now Member of Study Session Drug Protocol Review Committee for Agenzia Italiana del Farmaco (AIFA), Independent research on drugs funded by the Italian Medicines Agency (equivalent to the US FDA). Study session meets annually.
- 2008 –now Member of the Advisory Committee on Health Research of the Pan American Health Organization / World Health Organization (PAHO / WHO), appointed for initial 2 year term.
- 2007 Member / Rapporteur, WHO [World Health Organization] Expert Committee on the Selection and Use of Essential Medicines
- 2007 Member, Scientific Programme Committee, Cochrane Colloquium, Sao Paulo, Brazil
- 2006-now Member, Funding Arbiter Panel of the Cochrane Collaboration. Served as chair 2006-2010.
- 2005 Member, WHO [World Health Organization] Expert Committee on the Selection and Use of Essential Medicines
- 2005 Advisory Board for the Fifth International Congress on Peer Review in Biomedical Publication, Scientific Abstract Reviewer
- 2005 Elected Chair of the Funding Arbiter Panel for the Cochrane Collaboration. This group develops and monitors Cochrane Collaboration policy on COI.

- 2005 Scientific Programme Committee Member for Cochrane Colloquium, Melbourne.
- 2004-2010 Member, Cochrane Collaboration Steering Group. Elected Position (re-elected 2007).
- 2004 Advisory Committee Member, National Cancer Institute funded project “Translating Research into Policy” Anita Kohari, Principle Investigator.
- 2003 Advisory Board for the Fourth International Congress on Peer Review in Biomedical Publication
- 2003 Scientific Program Committee member, Cochrane Colloquium, Ottawa, 2004
- 2002 Search Committee member for a chief executive officer for the Cochrane Collaboration
- 2002-now eUICC Think Tank member
- 1999-2001 Planning Group for 2001 Cochrane Colloquium, Lyon, France
- 1999-2001 Advisory Board for the Third International Congress on Peer Review in Biomedical Publication
- 1999 Planning Committee, World Conference on Tobacco or Health
- 1997-1999 International Society for Technology Assessment in Health Care Scientific Advisory Committee (1999)
- 1996-2000 Cochrane Collaboration Steering Group. Elected position.
In 1997, I was elected Chair, Subgroup on Registration and Monitoring
- 1997-2000 Advisory Board for the Fourth International Congress on Peer Review in Biomedical Publication
- 1995 EURASSESS Committee, Dissemination Subcommittee. The purpose of this EC-supported committee is to develop a coordinated strategy for the implementation of findings of Technology Assessment Offices in the European Community.
- 1994-1997 Advisory Board for the Third International Congress on Peer Review in Biomedical Publication

Service to Scholarly and Professional Journals

- 2019-now Senior Editor, Research Integrity, Cochrane
- 2019-now Guest Editor, American Journal of Public Health, series on improving methods for evidence synthesis in public health
- 2019-2022 Guest editor, British Medical Journal series on Pathways to Independence: Reducing Commercial influence on health research, education and practice
- 2018-now Editorial Board member, Cochrane Library
- 2018-2022 Senior Editor, Cochrane Public Health and Health Systems Network

2016-now	Academic Editor, PLoS Biology, Meta-Research
2013-now	Member of Editorial Board, <i>Accountability in Research</i>
2010-14	Member of Cochrane Library Oversight Committee
2006-now	Member of Policy Advisory Board: <i>Journal of Clinical Epidemiology</i>
2005-2010	Chair, PLoS <i>Medicine</i> advisory group on competing interest and publication ethics
2006-now	Academic EI editor (approx. 2 times per year) for PLoS <i>Medicine</i>
2005-2006	Member of Editorial Consultants Board: <i>Journal of Clinical Epidemiology</i>
2000-2009	Senior Editor: Tobacco Control
2000-2007	Advisor for: <i>eBiomed</i> (an electronic collection of Journals)
1996-2013	Editor: Cochrane Collaboration Database of Systematic Reviews, Effective Professional Practice and Organisation of Care Section <i>The Effective Professional Practice and Organization of Care Group is conducting systematic reviews of the literature evaluating educational, financial, organizational and regulatory interventions to change the behavior of health care professionals.</i>
1998-2019	Member of Editorial Board: <i>International Journal of Pharmacy Practice</i>
1995-2002	Member of Editorial Board: <i>British Medical Journal</i>

Peer reviewer for:

2010-now	Environmental Health Perspectives
2010-now	Trials
2009-now	Archives of Internal Medicine
2007-now	The Cochrane Library
2007-now	Health Affairs
2006-now	Milbank Quarterly
2004-now	PLoS <i>Medicine</i> / PLoS <i>One</i> / PLoS <i>Biology</i>
2004-now	<i>Accountability in Research</i>
2003-now	The American Journal of Bioethics
2002-now	Social Studies in Science
2002-now	Science Communication

2002-now	Journal of General Internal Medicine
2000-now	Tobacco Control
1999-now	Health Education and Behaviour
1999-now	Journal of Law, Medicine and Ethics
1999-now	Journal of Health Services Research and Policy
1999-now	Annals of Internal Medicine
1999-now	Journal of Clinical Epidemiology
1999-now	International Journal of Pharmacy Practice
1997-2000	Controlled Clinical Trials
1995-now	American Public Health Association Journal
1995-now	Medical Care
1995-now	British Medical Journal
1995-2002	Evidence Based Medicine
1994-2002	Western Journal of Medicine
1993-now	New England Journal of Medicine
1993-now	Journal of the American Medical Association

Invited Lectures and Seminars

International

- 2024 Invited speaker. “Overview of the Evidence on Industry Influence on Research,” International Society for Environmental Epidemiology. Santiago. August 27.
- 2024 Invited speaker (with Lisa Parker. “Industry Influence within and Beyond Research.” World Conference on Research Integrity. Athens. June 4.
- 2024 Invited speaker. GECEI-PH Webinar titled "Big Pharma and Its Influence on Medicine." Feb 1st.
- 2023 Invited speaker. “Detecting and managing conflicts of interest in research.” Health Canada Science Seminar on Evidence-Informed Decision Making. Dec 12
- 2023 Invited speaker, “Industry influence on scientific research.” Evidence Policy and Influence Collaborative, University of Sydney Symposium on Commercial Determinants of health: unpacking industry influence. Nov 6.
- 2023 Invited speaker, “How to improve the Essential Medicines List process for the next 10 – 20 years.” World Health Organization, Nov 2.
- 2023 Invited plenary speaker. “Protecting the integrity of systematic reviews.” Cochrane Colloquium, London. September 5.
- 2023 Invited speaker. “Breaking the cycle of bias: Corporate influence on nutrition research and guidelines.” Centre for Clinical Epidemiology Seminar Series, McGill University, Montreal. January 10.
- 2022 Invited speaker. “Detecting and managing conflicts of interest in research” A*STAR’s Research Seminar and Workshop (A*RSW), Agency for Science, Technology and Research, Singapore. October 26.
- 2021 Guest lecturer and discussant lead. “Conflicts of interest in clinical research policy” for 24H - course "Evidence-based policy-making in health" as part of the Sciences Po Paris School of Public Affairs Global Health policy stream and practice, November 10
- 2021 Presenter and panel participant, “Conflict of Interest and Disclosure in Epidemiology,” Ramazzini Days, Carpi, October 29.
- 2021 Presenter, “Reflections from Cochrane’s Research Integrity Program,” at National Institute for Health Research Webinar Evaluation of Complex and Multi Component Interventions, London, September 23.
- 2021 Presenter and panel participant, “Conflict of Interest and Disclosure in Epidemiology,” International Society for Environmental Epidemiology (ISEE), New York, Aug 23-26.
- 2021 Presenter and panel participant, “ISEE principles for evidence synthesis,” International Society for Environmental Epidemiology (ISEE), New York, Aug 23-26.

- 2021 Symposium participant, “Promoting Environmental Health and Equity in a Shifting Climate,” International Society for Environmental Epidemiology (ISEE), New York, Aug 23-26.
- 2021 Invited Speaker. Wiley Science Talks with Cochrane: What journalists need to know about research integrity, June 30
- 2021 Invited Speaker. PharmedOUT Conference – Cutting the Cord: Curtailing Commercial Influence on Healthcare. “The Cochrane Library Conflict of Interest Policy – Why is it so strict?” June 18
- 2021 Invited Speaker. Academic Freedom in a Plural World: Global Critical Perspectives. “Industry sponsorship of research and conflicts of interest of researchers are a threat to academic freedom.” June 10
- 2021 Virtually Cochrane: Covid and beyond: Perspectives on how Cochrane can respond to the needs of users, April 21
- 2021 Presenter and discussant, “The Corporate Playbook: The Distortion of Science and other Strategies,” for A 21st Century Vector of Disease: Industry Influence on Health, Science and Democracy, San Francisco, April 1
- 2020 Invited Lecture: “Improving research integrity: A journal perspective.” REWARD / EQUATOR conference, Berlin, February 21.
- 2019 Hamilton Lecture and Medal. “Fighting Truth Decay: Building Transparency and Trust in Health Evidence,” Queen’s University, Belfast, November 27.
- 2019 Invited Plenary on Methodological Diversity. “What do you want? When do you want it? A Public Health Perspective,” Cochrane Colloquium, Chile, October 24. (Colloquium cancelled due to civil unrest, but lecture presented as part of virtual colloquium: <https://colloquium2019.cochrane.org/wed-4-dec> It can also be found on YouTube here: <https://youtu.be/aXz6TMrcwN8>
- 2018 Invited speaker: Ramazzini Days. “Corporate Influence on Research” Carpi, Italy. November 1, 2018
- 2018 Invited speaker: World Health Organization. “Methodological Challenges of Public Health Guidelines. Geneva, Switzerland November 9, 2018.
- 2018 Invited speaker: 34th Annual Meeting of the European Society of Human Reproduction and Embryology 2018. “Hidden and not so hidden bias in pharmaceutical research.” Barcelona. July 4, 2018
- 2017 Keynote speaker: International Congress on Peer Review and Scientific Publication, “Peer review: Are we looking at the right things?” Chicago, September 10, 2017
- 2017 Invited speaker: Royal Society of NSW and Four Academies Forum 2017, “The future of rationality in a post-truth world” Government House, Sydney, November 29, 2017

- 2016 Keynote speaker: Australasian Pharmaceutical Science Association (APSA) meeting, “New opportunities and challenges for evidence synthesis,” Dec 4, 2016.
- 2016 Invited speaker: Fiji National University, “Evaluating Systematic Reviews” and “The Cochrane Collaboration” September 12, 2016.
- 2015 Invited plenary: “Grand Challenges and Wicked Problems: Corporate Influence on Research,” Population Health Congress, Hobart, September 9
- 2015 Invited speaker: “Conflicts of interest of health care professionals,” Guidelines International Network Conference, Amsterdam, October 9.
- 2015 Invited plenary: “Industry tactics to manipulate public health research,” Oceania Tobacco Control Conference, Perth, October 21.
- 2015 Invited plenary: “Evidence and the Essential Medicines List,” ISDM-ISEHC, Sydney, July 20.
- 2014 Distinguished Lectureship: “Hidden and not so hidden biases in drug studies” McGill University and Lady Davis Institute for Medical Research, Montreal (April 7 – 8)
- 2013 Invited Plenary: “Cochrane reviews travel the world: But the evidence can only take you so far” Cochrane Colloquium, Quebec City (September 20)
- 2012 Invited Speaker: “Bias in drug studies” University of Sydney, Faculty of Pharmacy Research Seminar, Sydney (April 17)
- 2012 Invited Speaker and Workshop leader: “Influence of Reporting Bias on Drug Reviews,” “Risk of Bias Assessment,” workshop on assessing risk of bias in drug studies, Department of Health and Aging, Australian Government, Canberra (April 23)
- 2012 Invited Keynote Speaker: “Bias in reports of drug studies: Why are independent drug bulletins important?” International Society for Drug Bulletins General Assembly Meeting, Vancouver (March 25)
- 2011 Invited Speaker: “Ghosts, guests and other distortions of authorship in medical and scientific journals,” COPE (Committee on Publication Ethics) North American Seminar and Forum, San Diego (November 1)
- 2011 Invited Speaker: “The Cochrane Collaboration and Clinical Practice Guidelines,” Estonian Health Insurance Fund and World Health Organization. Tallin, Estonia (September 7)
- 2011 Invited Speaker: Reporting bias in drug trials: What you don’t know could hurt you.” Fraser Health Research Ethics Board Annual Education meeting. Vancouver, Canada (January 29).
- 2010 Invited Plenary Speaker: “Light at the top: A vision for Leadership in a changing world” Joint Colloquium of the Cochrane and Campbell Collaborations. Keystone, CO. (October 22)

- 2010 Invited Speaker: “Outcome reporting bias in drug trials: Does it matter?” Department of Anesthesiology, Pharmacology and Therapeutics Seminar, University of British Columbia. Vancouver, CA (September 9)
- 2010 Invited Speaker: “Outcome reporting bias in drug trials: Does it matter?” Therapeutics Initiative Seminar. Vancouver General Hospital. Vancouver, CA (September 9)
- 2010 Invited Speaker: “International ethical guidelines regarding inclusion of children in clinical trials” StaR Child Health Conference. Vancouver, CA (September 10)
- 2010 Invited speaker: “Marketing of Medicines: Trends in Pharmaceutical Research, Education and Promotion Policies. University of Modena. Modena, Italy (July 6)
- 2010 Keynote speaker: “An analysis of new models for academic-industry relationships” Workshop on models for pharmaceutical industry and public health department collaborations. Regione Emilia-Romagna. Bologna, Italy (July 7)
- 2010 Invited keynote speaker: “Conflicts of interest in medical research: Managing the unmanageable” Conference on Research and Innovation. Bologna, Italy (January 18)
- 2010 Invited Speaker: Taming the Beast: Managing Conflicts of Interest in Research” World Health Organization (February 26)
- 2010 Invited Speaker: “Evidence: Can we Trust it?” at Evidence on Trial: Has it made an impact on health? Auckland, New Zealand (March 22)
- 2009 Invited Speaker: “Tainted evidence on drugs” International Cochrane Symposium. Evidence-based Medicine and Systematic Reviews: Challenges and Opportunities. Copenhagen, Denmark (April 22)
- 2008 Invited Plenary Speaker: “Hidden and not so hidden biases in clinical trials” 2nd South Asian Regional Symposium on Evidence Informed Health Care ‘Investing in Evidence for Better Health’ Vellore, India (April 9)
- 2007 Invited Speaker: “Hidden and not so hidden biases in clinical research.” British Columbia Agency Annual Cancer Conference, UBC BCCA Research Ethics Board Presentation. (November 20).
- 2007 Invited Speaker: “Spinning your trial results: What is the future of traditional journals?” for special session of XV Cochrane Colloquium, Sao Paulo, Brazil (October 24)
- 2007 Invited Plenary Speaker: “Tobacco Industry Manipulation of Research” Public Ceremony in Cancer Prevention organized by Regional Authority of Piemonte, Regional Center for Cancer Prevention Piemonte, and Unit of Cancer Epidemiology at University of Torino. Torino, Italy (May 31). *This event also included me presenting awards to high school and medical students who were active in tobacco control.*
- 2007 Invited Speaker: “The Cochrane Collaboration: Minimizing Influence of Commercial Organizations.” Beyond the Evidence Symposium. Amsterdam (April 18)

- 2007 Invited Speaker and Participant: “Country Bias in Peer Review” Peer Review Editors Conference organized by ESE:O (escritura para liderar). Buenos Aires (February 22-24).
- 2006 Invited Speaker: “Corporate Abuses of Science.” European Environment Agency meeting on “Late Lessons from Early Warnings” Copenhagen (April 6)
- 2006 Invited Plenary Speaker: “Maintaining Momentum: What We Should be doing more of in Tobacco Control.” World Conference on Tobacco or Health. Washington, D.C. (July 12).
- 2006 Invited Speaker: “Factors Associated with Results and Conclusions of Published Randomized Controlled Trials of Drug-Drug Comparison.” Cochrane Colloquium. Dublin, Ireland (October 23-26)
- 2004 Invited Speaker: “Health Policy – Where’s the Evidence?” National Institute of Clinical Studies, Australia. Workshop. (October 22).
- 2004 Invited Speaker: "Outcomes of Interventions in Pharmacy Practice: Today's Evidence" for a Symposium on Optimizing Pharmacotherapy in Practice at Danish University of Pharmaceutical Sciences, Drug Research Academy (September 16).
The half day symposium was followed by a half day meeting with graduate students to discuss research methods and their ongoing projects.
- 2004 Invited Speaker: Managing the Unmanageable: Financial Ties between Researchers and their Sponsors. 8th World Congress on Clinical Pharmacology and Therapeutics, Brisbane, Australia (August 4)
- 2004 Special Seminar: Influencing Policy: Tobacco Industry Manipulation of Research. School of Population Health. University of Queensland, Brisbane, Australia (August 4).
- 2003 Invited Speaker and Chair: Conflicts of Interest. Cochrane Colloquium. Barcelona, Spain (October 27)
- 2003 Guest Lecturer: Industry-sponsored Research: The Good, The Bad and the Biased. University of Sydney. Sydney, Australia (March 26)
- 2003 Invited Speaker: Everything but the Evidence. Aspects of Evidence Symposium. Melbourne, Australia (March, 29)
- 2002 Invited Speaker: Analysis of Public Commentary on the Framework Convention on Tobacco. World Health Organization (March 18)
- 2002 Plenary Speaker: Case Studies of the Role of Research in the Development of Indoor Air Policies. Indoor Air 2002, Monterey (July 2)
- 2001 Plenary Speaker: The Role of Special Interest Groups in Influencing Data on Risk. World Health Organization / UK Department of Health meeting on Risk Communication – in preparation for 2002 World Health Report on Risk, London, England (October 24)

- 2001 Plenary Speaker: Conflict of Interest Panel. International Society for Technology Assessment, Philadelphia, Pennsylvania (June 4)
- 2000 Plenary Lecture: Tools for Assessment of Individual Patient Outcomes. European Society of Clinical Pharmacy 29th European Symposium on Clinical Pharmacy, Basel, Switzerland (October 14)
- 2000 Workshop Coordinator: Confidentiality Issues of Observational Research. European Society of Clinical Pharmacy 29th European Symposium on Clinical Pharmacy, Basel, Switzerland (October 14)
- 2000 Invited Speaker for Debate: Tobacco Control's Involvement with the Tobacco Industry. 11th World Conference on Tobacco or Health, Chicago, IL (August 10)
- 1999 Plenary Lecture: Translating Research into Policy, Meeting of the Denmark Medical Research Council and Health Technology Assessment Agency. Copenhagen, Denmark (September 30)
- 1999 Invited Speaker: Workshop on the Cochrane Collaboration and Health Technology Assessment Agencies. Rome, Italy (October 7)
- 1998 Peer Review and the Cochrane Database of Systematic Reviews. Cochrane Colloquium, Baltimore, MD (October 22)
- 1998 The Quality of Cochrane Products as Perceived by those Outside of the Cochrane Collaboration. Cochrane Colloquium, Baltimore, MD (October 23)
- 1998 Labelle Lectureship in Health Services Research: "Evidence-Based Policy: Oxymoron or Just Plain Moronic?," McMaster University, Ontario, Canada (October 15)
- 1998 Plenary Lecture: "Criticizing Criticism." United Kingdom Cochrane Collaboration Contributors' Meeting, Oxford, England (April 3)
- 1997 Plenary Lecture: "Using Research to Change Health Policy." Clinical Cancer Research Conference, Geneva Park, Canada (November 4)
- 1997 Panel Presentation: "Using Systematic Reviews of Organizational Interventions to Change Policy." International Conference on the Scientific Basis of Health Services, Amsterdam (October 8)
- 1997 Panel Presentation: "Electronic Peer Review of the Cochrane Database of Systematic Reviews." International Congress on Peer Review and Biomedical Communication, Prague (September 21)
- 1997 Plenary Lecture: "Quality Assurance and the Cochrane Collaboration." Aberdeen Cochrane Day, Aberdeen, Scotland (May 1)
- 1996 Plenary Lecture: "Quality Assurance and Cochrane Reviews." Cochrane Colloquium, Adelaide, Australia (October 23)
- 1996 Demonstration of the Cochrane Database. Meeting of the International Society of Technology Assessment in Health Care, San Francisco, CA (June 23)

- 1995 "Protocol Development: The Effect of Expanding Pharmacists' Roles on Health Services Utilization, the Costs of Health Services, and Patient Outcomes." Part of Training Workshop for the Cochrane Collaboration of Effective Professional Practice, York, UK (April 7)
- 1995 Invited Presentation: "The Quality of Published Drug Studies." National Institute of Public Health, Oslo, Norway (February 6)
- 1994 Plenary Lecture: "The Scientific Adequacy of Published Research: It's Influence on Public Policy." International Society for Technology Assessment in Health Care, Baltimore, MD (June 20)
- 1993 Invited Presentation: "Evaluation of a Problem-Based Teaching Module for Teaching Rationale Prescribing." Asian Conference on Clinical Pharmacology, Yogyakarta, Indonesia (October 31 - November 4)
- 1991 Invited Presentation: "Teaching Pharmacology – Some New Ideas." World Health Organization meeting on Good Prescribing. Groningen, The Netherlands (June 10-14)

National

- 2024 Invited Panelist. AAMC Forum on Conflicts of Interest. Beyond the 2009 NAS Report on Conflicts of Interest. Baltimore. April 25.
- 2024 Invited Panelist. How industry documents have been used to reveal strategies and tactics that corporations use to undermine science and policy. University of California San Francisco Program on Health and the Environment. San Francisco. January 9.
- 2023 Invited panel speaker, "Commercial Determinants of Health," Boston University School of Public Health, Boston, March 7.
- 2022 Invited opening speaker, "Overview of the evidence on sponsor influence," National Academies of Science, Engineering and Medicine workshop on Sponsor Influence on Research, Washington DC, December 14.
- 2022 Invited speaker, "How to be a research detective: Developing a method to identify problematic studies," CCTES seminar, Johns Hopkins University, Baltimore, December 1.
- 2022 Invited speaker, "Conflicts of Interest in Research and Practice," Biomedical Research Integrity Seminar Series, University of Washington, August 30.
- 2022 Invited speaker, "Triangulation: Nothing new about using the best evidence to answer a question," National Academies of Science, Engineering and Medicine Workshop to Support EPA's Development of Human Health Assessments: Triangulation of Evidence in Environmental Epidemiology, Washington D.C., May 11.
- 2021 Invited speaker, "Introduction to Cochrane Public Health Reviews: Focus on summarizing findings without meta-analysis," US Environmental Protection Agency Community of Practice, September 14.

- 2021 Grand Rounds Invited Speaker, “Evidence, Policy, Influence, Collaboration.” Institute for Health Policy Studies Grand Rounds, UCSF, Aug 18
- 2021 Invited speaker, “Conflicts of Interest in Medical Research, Education and Practice,” for Doctors for America Webinar, September 2.
- 2021 Invited speaker, “Evidence, Policy and Influence” PORTAL presentation, Harvard, February 18
- 2019 Plenary speaker: “Hidden and not so hidden bias in research,” Australian Research Management Society Conference, Adelaide, Sept 18.
Also conducted a Research Integrity Workshop, Sept 17
- 2019 Keynote speaker: “Fighting Truth Decay: How to navigate health in a post-Truth world,” Independent Commission against Corruption, Sydney, Aug 15.
- 2019 Keynote speaker: “Hidden and not so hidden bias in research,” and Workshop leader: “Conflicts of Interest,” Australian Association of Research Managers, Adelaide, Sept 17-18
- 2017 Keynote speaker: “Conflicts of interest – a threat to academic integrity,” Australasian Symposium on Academic Integrity and Public Trust, Sydney, Nov 6
- 2017 Invited speaker: “Influences on Evidence: Putting the cart before the horse,” Royal Society of New South Wales and Four Academics Forum, Government House, Sydney, Nov 29.
- 2016 Guest Lecture: “Conflicts of Interest and Guideline Development,” NHMRC Guideline Developer Meeting, Melbourne, July 30
- 2016 Conflict of Interest workshop. National Prescribing Service. September 15
- 2016 Invited Lecture: Systematic Reviews: How far can we go?” Food Standards New Zealand Australia, Canberra, May 26
- 2014 Guest Lecture, Humanities in Medicine Lecture Series. “Drug studies: the good, the bad and the biased” Duke University, Durham, North Carolina (April 22)
- 2013 Invited Speaker: “Name that bias: Lessons learned from empirical studies of bias in clinical research” National Toxicology Program, Raleigh, North Carolina (May 20)
- 2012 Invited Speaker: “A systematic review of quality assessment tools for published animal studies” National Toxicology Program, Raleigh, North Carolina (February 6)
- 2011 Invited Speaker: “Impact of Reporting Bias on Information about Drugs” FDA/CDER Seminar Series at Food and Drug Administration, White Oak, Maryland (September 21)
- 2011 Invited Speaker: “Outcome Reporting Bias: What you don’t know could hurt you” at Advanced Study Weekend, The McDougall Health and Medical Center, Santa Rosa. This is national meeting of health care providers and consumers. (February 19)

- 2010 Invited Speaker: “Ethics and International Collaboration” Institute of Medicine, Government-University-Industry Research Roundtable Working Group on International Research Collaborations. Examining Core Elements of International Research Collaboration: A Workshop (July 26)
- 2010 Invited Speaker: “Marketing of Medicines” at Critical Prescribing Skills: Advances from the Attorney General, Chicago (May 13)
- 2010 Invited Speaker: “Detecting Conflicts of Interest” American Association of Health Care Journalists, Chicago (April 23)
- 2010 Invited Speaker: “Marketing of Medicines Curriculum” at Critical Prescribing Skills: Advances from the Attorney General Consumer and Prescriber Education Grant Program. Chicago (May 13)
- 2008 Invited Speaker: “Faulty Clinical Trials and Financial Conflicts of Interest” The 45th Annual New Horizons in Science Conference, Council for the Advancement of Science Writing. Palo Alto (October 28)
- 2008 Invited Speaker: for 2 presentations: “Buyer Beware: The Marketing of Medicines is Risky Business” and “Drug Studies: The Good, the Bad and the Biased” at Advanced Study Weekend, The McDougall Health and Medical Center, Santa Rosa. This is national meeting of health care providers and consumers. (September 6)
- 2008 Invited Speaker: “Working together or working apart: Cross-group cooperation in priority setting. United States Cochrane Center Meeting on Priority Setting in Systematic Reviews. Baltimore (July 11)
- 2007 Invited Speaker: “The Methods and Uses of Systematic Reviews” and “Why some Statins appear more efficacious than others.” Making More Effective Use of Evidence-Based Research, A meeting sponsored by the Reforming States Group and Milbank Memorial Fund. (September 18 – 19)
I also served as a small group discussion leader for this meeting of members of the judicial, legislative and executive branches of state government.
- 2005 Invited Speaker: “Analyzing Systematic Reviews and Meta-analyses” Science for Judges VI. Brooklyn Law School, Brooklyn, New York (November 5). Also led 2 workshops for federal judges (November 4 and 5).
- 2005 Keynote Speaker: “Tobacco Industry Research: The Good, the Bad and The Biased” California Tobacco Related Disease Research Program Meeting (October 10)
- 2005 Invited Speaker: “Moral Disengagement Strategies” National Cancer Institute Tobacco Control Investigator’s Meeting, Synthesizing Research for the Public’s Health. (May 3)
- 2004 Invited Speaker: “The Limits of Competing Interest Disclosures” Council of Scientific Editors National meeting. Chicago, IL (October 30)
- 2004 Invited Discussant: The Coronado Conference II: Sequestered Science – The Consequences of Undisclosed Knowledge. New York, NY (October 14-15)
- 2004 Invited Speaker: (2 talks) “What is Evidence? Assessing Studies and Presentations for Evidence” and “Smokescreen: Tobacco Industry Manipulation of Research” 13th

- Annual Kaiser Permanente National Internal Medicine and Family Practice Symposium, Hawaii (July 18 and 22)
- 2004 Invited Speaker: “Tobacco Industry Attacks on Science: No Issue to Large or Too Small” National Cancer Institute Tobacco Control Investigator’s meeting, Synthesizing Research for the Public’s Health. (June 2)
- 2004 Invited Speaker: “Does Funding Source Influence Research Integrity?” Society of Toxicology, Baltimore (March 24)
- 2003 Invited Speaker: “Financial Conflicts of Interest.” *Today’s Research, Tomorrow’s Issues*. A National Human Subjects Protections Conference, San Francisco (September 23).
- 2003 Invited Speaker: “Smokescreen: Tobacco Industry Manipulation of Research.” *Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy*, The Center for Science in the Public Interest, Washington, D.C. (July 11)
- 2003 Invited Speaker: “Tobacco Industry Influence on Scientific Publication.” Tobacco Industry Documents Research Investigators Meeting and Tobacco Synthesis meeting, Washington, D.C. (June 17)
- 2003 Invited Speaker: “Is the Tobacco Industry Different from Other Industries?” Tobacco Industry Funding Workshop, New Orleans (February 22)
- 2002 Invited Speaker: “Preliminary Results of Research on Managing Conflicts of Interest” Office of Research Integrity meeting (November 17)
- 2002 Invited Speaker: “Case Examples: Managing Conflicts of Interest” National Institutes of Health meeting on Conflicts of Interest (September 30)
- 2002 Plenary Lecture: Industry Sponsored Tobacco Research. American Association of Medical Writers, Houston (September 19)
- 2002 Invited Speaker: “Managing Conflicts of Interest” Washington University Conference on Conflicts of Interest and Research Integrity (April 16)
- 2002 Grand Rounds, Mount Sinai Medical Center, New York. “Managing Conflicts of Interest” (January 17)
- 2001 Plenary Lecture: “Conflicts of Interest in Clinical Trials” American Society for Rheumatology, San Francisco (November 12)
- 2000 Plenary Lecture: “Academic Industry Relationships” Office of Research Integrity Conference on Research Integrity, Washington D.C. (November 13)
- 1999 Invited Speaker: “Communicating Research to the Media.” Gerontological Society of America. (November 19).
- 1996 Plenary Lecture: "Research Careers." for the American Youth Leadership Forum, San Francisco, CA (July 11)

- 1996 Pre-Conference workshop: "Quality Assurance and the Cochrane Collaboration." American Association for Health Services Research, Atlanta, GA (June 9)
- 1995 Plenary Lecture: "Published Drug Studies: The Good, the Bad and the Biased." National Meeting of the Association of Rheumatology Health Professionals, San Francisco, CA (October 25)
- 1993 "Medical Literature: The Good, the Bad and the Biased." Syntex, Inc., Palo Alto, CA (December 14)
- 1991 "Implications of Federal Policies on Pharmaceutical Marketing and Promotional Institute for the Future." Institute for the Future. Menlo Park, California (July 11)
- 1990 "Forging a Women's Health Research Agenda." Presentation Workshop on Clinical Pharmacology, sponsored by National Women's Health Resource Center. Washington, DC (December 5-6)
- 1990 "Validation of an Instrument for Assessing Physician Prescribing Practices." Workshop on Health Outcomes Assessment Measurement, American Public Health Association meeting. Chicago, Illinois (September 30)
- 1989 "High School Students' Questions about Crack Cocaine." Presented at "Crack: A Scourge on Education, Health and Social Services." National Health Policy Forum, George Washington University. Washington, DC (August 8)

Local

- 2019 Invited Speaker. Mechanisms for Fighting Truth Decay. Independent Commission Against Corruption (ICAC) Network, Sydney, August 21.
- 2019 Invited Speaker. Design, Conduct and Publication of Research: Problems and Solutions. NeuRA Institute. Neuroscience Research Australia, Sydney, May 24.
- 2018 Invited Speaker. Fighting Truth Decay. Sydney Ideas. University of Sydney, October 10.
- 2017 Invited Speaker. Is Truth Dead? From Power and the Media to Science and Reason. Post-Truth Initiative end of year event. University of Sydney, Nov 20.
- 2016 Invited Speaker. "Hidden and not so hidden bias in Nutrition Research," Australian Institute of Health Innovation, Macquarie University (May 25)
- 2012 Invited Speaker. "Selective reporting of drug trials: What you don't know won't help you... or could hurt you," Stanford Prevention Research Center / General Internal Medicine Seminar. Stanford University, Palo Alto (June 7)
- 2012 Panel Discussion Participant. "Does Corporate Funding Corrupt Science?" Wonderfest: The Bay Area Beacon of Science. Stanford University, Palo Alto (March 2)

- 2011 Speaker. Cochrane Methodology Reviews. Policy, Science, and Resources for Comparative Effectiveness Research: A Symposium. University of California, San Francisco (January 10)
- 2009 Grand Rounds Speaker. Research as Marketing. Psychiatry Grand Rounds, Alta Bates Summit Medical Center (April 6)
- 2009 Invited Speaker. Evaluating Systematic Reviews and The Cochrane Collaboration. Alcohol Research Group, Berkeley, CA (Jan 20)
- 2008 Invited Speaker. Research or Marketing? Lecture for Pharma Free UCSF Student Group. UCSF. (Dec 3)
- 2008 Invited Speaker. Meta-analysis and the Cochrane Collaboration. Division of General Pediatrics Research Seminar, UCSF. (July 16)
- 2008 Invited Speaker: Changing the Face of Science. San Francisco chapter of the Association for Women in Science (sFAWIS) (February 13)
- 2008 Invited Speaker: Hidden and not so hidden biases in clinical research. Patient-Oriented Research Talk (PORT), VA Medical Center, San Francisco (January 18)
- 2008 Invited Speaker: Pharmaceutical Research as Marketing. PharmFree Student Lecture, University of California, San Francisco (January 10)
- 2007 Invited Speaker: Great American Smokeout Event. "Tobacco Industry Manipulation of Research and Policy." San Francisco (November 14)
- 2007 UCSF General Medical Education Grand Rounds. "Bias in drug trials: How to spot it and what to do about it" San Francisco (October 16)
- 2007 Invited Speaker: American Society of Health Care Journalists. "Conflict of Interest in Health Care: How to Spot it, What to do about it." San Francisco (May 8)
- 2006 Invited Speaker: UC Davis American Medical Students Association Grand Rounds. "When is Research Research or Marketing?" Davis (November 2)
- 2006 Invited Speaker: American Society of Science Writers. "Drug Marketing by Many Other Names: How Drug Industry Marketing Invades Research, Education and Treatment." San Francisco (October 10)
- 2006 UCSF Mini Medical School. "Risky Business: Reporting on Research in the Lay Press." (May 3)
- 2005 Grand Rounds: UCSF Laboratory Medicine. "Managing the Unmanageable: Conflicts of Interest and Clinical Trials" (January 3)
- 2005 Grand Rounds: UCSF Medicine. "Managing the Unmanageable: Financial Ties between Researchers and their Sponsors" (February 24)
- 2005 Invited Speaker: "Conflicts of Interest and Clinical Trials." UC Irvine Task Force on Conflicts of Interest (February 26)

- 2005 Invited Speaker: “The Policy of Science and Health: Getting Things Done!” Graduate Students’ Association 20th Annual Career and Research Days. (April 6)
- 2004 Invited Speaker: “The Framework Convention on Tobacco Control: EU and US Differences” European Union Center, Pomona University (March 29)
- 2003 Keynote Speaker: “Smokescreen: How the Tobacco Industry Manipulated Research” American Lung Association of California Annual Conference, Sacramento (September 20).
- 2003 Invited Speaker: “Conflicts of Interest and Academic Industry Relations,” BioEntrepreneurship Symposium: Walking the Tightrope, San Francisco (June 25)
- 2003 Invited Speaker: “Corporate and Economic Pressures on Academic Freedom,” Academic Freedom Forum, Berkeley (June 11)
- 2003 Panel Participant, UCSF, “Paths to Science: How do Education and Training Shape Women’s Experiences in Science and Medicine?” (May 5)
- 2003 Invited Speaker: “Direct to Consumer Drug Advertising of Prescription Medications,” Hot Topics in Pharmacy Program, Sacramento (March 21)
- 2002 UCSF Symposium on Peer Review, San Francisco, “Conflicts of Interest and Peer Review” (November 6)
- 2001 Cancer Center, University of California, San Francisco, “A Medley of Tobacco Industry Document Projects” (November 20)
- 2001 Institute for Health Policy Studies, University of California, San Francisco, “The Cochrane Collaboration” (November 5, 2001)
- 2001 MERC/CADC Seminar, University of California San Francisco, “The Cochrane Collaboration: Methods for Conducting and Disseminating Systematic Reviews” followed by a discussion of the application of these methods to diverse populations (February 6)
- 2001 HEELP Conference (Health, Economics, Ethics, Law and Policy), UCSF Hospital. “Risky Business: Reporting on Research in the Lay Press” (January 31)
- 2000 UCSF Cancer Center, Tobacco Program Seminar. “The Role of Research in Policy Development: Case Studies in Tobacco Control.” (November 28)
- 2000 Speaker, UCSF School of Pharmacy Homecoming. “The Risky Business of Risk.” (November 9)
- 2000 Grand Rounds: Department of Pediatrics, San Francisco General Hospital. “Drug Studies: The Good, the Bad, and the Biased.” (October 3)
- 2000 “Health Policy Careers” Graduate Student Association Research Day, University of California, San Francisco (February 3)
- 2000 “Risky Business,” Brown Bag Seminar, University of California, San Francisco (March 8)

- 2000 Mentor Dinner Speaker: Informal discussion with UCSF postdoctoral fellows, graduate students and professional students (May 9)
- 1998 "Role of Research in Policy Development." California Tobacco Education and Research Oversight Committee. Oakland (May 4)
- 1998 Co-chair and Key Note Speaker. California Tobacco Related Disease Research Program Annual meeting. San Diego, CA (December 10)
- 1997 "The Cochrane Collaboration." Rounds for Medical Residents, San Francisco General Hospital, San Francisco, CA (October 22)
- 1997 "Writing Grants or How to get \$1.5 Million the Hard Way." Research in Development Seminar, Department of Clinical Pharmacy, UCSF (July 7)
- 1996 "Getting the Evidence: The Electronic Future." Medical Grand Rounds, University of California, San Francisco, CA (Sept 2)
- 1996 "The Cochrane Collaboration." Invited presentation for the Center for AIDS Prevention Studies Fellowship Program, San Francisco, CA (May 7)
- 1996 "How to get your First Grant." Invited presentation for the Center for AIDS Prevention Studies Fellowship Program, San Francisco, CA (May 7)
- 1995 "The Tobacco Industry and Scientific Publication." Invited presentation for Tobacco Control Research Network, Berkeley, CA (December 1)
- 1995 "Evaluating the Effects of Organizational Change in Health Care: Can it be done?" Research in Development Seminar, Division of Clinical Pharmacy, UCSF (November 30)
- 1995 "The Quality of Drug Studies: Instrument Design." Invited presentation for Stanford University Hospital Department of Pharmacy (April 19)
- 1995 "Evaluating Pharmaceutical Services." Invited presentation for South Bay Pharmacists (April 19)
- 1995 "The Cochrane Collaboration: International Effort to Conduct and Disseminate Results of Meta-Analyses for Medicine." Department of Epidemiology and Biostatistics, University of California, San Francisco (March 14)
- 1994 Panel Member for "Women Scientists in Alternate Careers." for Women in Life Sciences / Association of Women in Science (November 19)
- 1994 "Sponsored Symposia Supplements: A Health Policy Research Odyssey." Division of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA (October 19)
- 1994 "Order out of Chaos: Conducting Structured Reviews of the Medical Literature." Institute for Health Policy Studies Health Policy Seminar Series, San Francisco, CA (October 31)

Curriculum Vitae
Lisa Anne Bero

- 1993 "Evaluating the Quality of the Medical Literature: The Good, the Bad and the Biased." VHA Pacific Drug Utilization Task Force, Walnut Creek, CA (November 11)
- 1992-1993 "Public Speaking without Fear: How to Give a Good Seminar." presentation included a videotape on "Acting Techniques for Lecturers," by Dan Gunther, Institute for Health Policy Studies (March 16)
- 1990 "Psychotropic Medications." Bay Area Addiction and Research Treatment Clinics, San Francisco (January 17)
- 1989 "Studying Physician Prescribing Habits." Topics in Therapeutics Seminar, Division of Clinical Pharmacology, School of Medicine, University of California, San Francisco (November 3)

RESEARCH & CREATIVE ACTIVITY

Current Research Programs and Creative Activity

- (1) Bias / Research on Research Integrity
 - Quantitative and qualitative studies examining bias in the design, conduct and publication of research
 - Quality of the medical literature
 - Dissemination of research and effect on clinical practice and health policy
 - Corporate influence on research and publication
 - Commercial determinants of health
- (2) Meta-analysis / systematic review / evidence synthesis
 - Methods development and quality assessment
 - Publication bias, assessment of risk of bias
 - Application of systematic review methods in public health
- (3) Pharmaceutical policy
 - Development, dissemination, and implementation of prescribing guidelines
 - Formularies
 - Essential Medicines
 - Comparative effectiveness of pharmaceuticals
- (4) Tobacco Control Policy
- (5) Methods for environmental hazard and risk assessment

Research Awards, Fellowships and Extramural Grants (only awards on which I am Principal Investigator are listed)

- | | |
|-----------|---|
| 2022-2025 | National Institute of Health Research (UK). With Jack Wilkinson, University of Manchester. Research for Patient Benefit Grant (149,999 BP). Developing and evaluating a tool to protect patients from fabricated data in health systematic reviews. |
| 2018-2021 | National Health and Medical Research Council (CI-A). Project Grant (\$980,000). Improving the Evidence Base for Public Health Guidelines. |
| 2018-2021 | National Health and Medical Research Council (CI-F). Project Grant (\$700,000) Methods for meta-analysis of interrupted time series analyses |
| 2017 | Sydney Policy Lab (CI). (\$26,000) Improving methods to evaluate evidence in support public health guidelines to protect Australians from environmental health hazards |
| 2017 | Sydney Policy Lab (co-CI). (\$28,000) Setting the standard for consumer data sharing practices of top-rated health apps |
| 2017-19 | Principal Investigator (\$252,000) Research Compact. Pharmaceutical Policy Program. |

- 2017-19 National Health and Medical Research Council (CI-D), Project Grant (\$1,002,283). How best to protect public health: a comparative analysis of regulatory safety warnings on medicines in Australia, Canada the European Union and the United States.
- 2014 Research Award (\$45,000) California Breast Cancer Research Program. Systematic review of policy interventions to reduce exposure to chemicals.
- 2012-2014 Research Award (\$114,532) from The Cochrane Collaboration Methods Innovation Fund, "Searching for Unpublished Trials"
- 2011-2013 Research Award (\$412,500) from Office of Research Integrity / National Institute of Environmental Health Sciences (NIH), "Measuring Design, Reporting and Funding Bias in Nonclinical Research"
- 2007-2011 Research Award (\$995,414) from the Flight Attendants Medical Research Institute, "Implementing the Evidence"
- 2006-2009 Research Award (\$400,000) from the Attorney General Prescribing Grant Program, "Development and Evaluation of a Curriculum for Improving Prescribing Practices"
- 2005-2006 Research Award (\$155,380) from the National Science Foundation, "Public Attitudes about Financial Ties of Researchers"
- 2004-2007 Research Award (\$420,000) from the Tobacco Related Disease Research Program, "Corporate Strategies: Design, Conduct and Publication of Research"
- 2003-2005 Research Award (\$325,000) from the Flight Attendants Medical Research Institute, "Development of Smoking Restrictions on Airlines"
- 2002-2007 Research Award (\$1,123,811) from the Flight Attendants Medical Research Institute, "Development and Implementation of Smoking Restriction Policies"
- 2002-2004 Research Award (\$200,000) from the National Institutes of Health, "Qualitative Study of Editorial Decision-Making" (1RO1 NS44500-01)
- 2001-2003 Research Award (\$200,000) from the National Institutes of Health, "Management Decisions in Financial Conflicts of Interest" (1RO1 NS-42398)
- 2000-2003 Research Award (\$442,670) from the California Tobacco-Related Disease Research Program, "Analysis of Tobacco Industry Document on Scientific Research" (#9RT-0193)
- 1998-1999 Research Award (\$43,000) from the Industry-University Cooperative Research Program, "Development of a Faculty Financial Disclosure Database" (P98-09)
- 1998-2000 Research Award (\$315,838) from the California Tobacco-Related Disease Research Program, "Implementation of California AB13: Smoking Ban in Bars " (#7RT-0180)
- 1997-2000 Research Award (\$703,808) from the National Institutes of Health, National Cancer Institute, "Developing Policy to Reverse the Cigar Trend" (#RO1 CA76972-01)
- 1997-2000 Research Award (\$335,000) from the American Cancer Society, "Improving the Use of Research for Policy: Case Studies in Tobacco Control" (#RPG-97-143-01-PBP)

- 1997-2000 Research Award (\$249,785) from the California Tobacco-Related Disease Research Program, "Roles of Media and Community Response in the Recent Cigar Trend" (#6RT-0026)
- 1997-2000 Research Award (\$331,211) from the California Tobacco-Related Disease Research Program, "Case Studies of Indoor Air Regulation: Role of Research" (#6RT-0025)
- 1994-97 Research Award (\$280,517) from the Robert Wood Johnson Foundation, "Use of Tobacco Industry-Sponsored Research to Influence Policy" (#024783)
- 1993-94 Research Award (\$133,348) from the California Tobacco-Related Disease Research Program, "Quality of Tobacco Industry-Funded Research" (#4RT-0035)
- 1993 Research Award (\$5000) from the American Association of Retired Persons to Study Quality of Drug Studies
- 1993 Grant (\$2800) from Kaiser Family Foundation to do Citation Analysis
- 1993 Contract (\$5000) from National Cancer Institute to Study Citation of Tobacco Industry-Sponsored Symposia
- 1992 Joint grant from Amgen, Inc. and Glaxo, Inc. (\$5000) "Evaluation of the Mandatory Patient Consultation Regulation"
- 1991-94 Career Development Award (\$220,709) from the California Tobacco-Related Disease Research Program, "The Tobacco Industry and Scientific Research" (#2KT0072)
- 1991 Research Award (\$5000) from the American Association of Retired Persons to Study Pharmaceutical Industry Sponsored Symposia
- 1988-90 Pew Fellowship in Health Policy
- 1987-88 National Institute on Drug Abuse Individual National Research Service Award. Research performed in the Department of Pharmacology, University of California. San Francisco, California
- 1986-88 Pharmaceutical Manufacturers Association Predoctoral Fellowship
- 1985 American Society for Pharmacology and Experimental Therapeutics Graduate Student Travel Award
- 1984-85 Junior Investigator Research Grant from Innovative Research of America. Rockville, Maryland
- 1983-85 Pharmacological Sciences Training Grant/NIH Predoctoral Award

Other Creative Endeavor

Conduct workshops for consumers and journalists on identifying and reporting on conflicts of interest in science.

I was a delegate for the World Health Assembly 2011 and 2012, representing the Cochrane Collaboration as an NGO in official relations with the World Health Organization

Director, World Health Organization Collaborating Centre on Pharmaceutical Research and Science Policy (2010 – 2014)

Lead on application of the Cochrane Collaboration to be an NGO in official relations with the World Health Organization (WHO), approved January 2011. I am a Cochrane Collaboration designated official in collaboration with WHO.

I participated in a the Coro-UCSF Leadership Training course (64 hours) (2006)

I have developed a research and business proposal for a “Center for Research Integrity and Science Policy”

Developed a curriculum for health professionals focused on pharmaceutical industry marketing practices. (Development and evaluation funded by the Attorney General Consumer and Prescriber Grant Program)

I am a member of a national “Conflict of Interest Working Group” convened by Mildred Cho, Ph.D., Stanford University. The 50+ member multi-disciplinary group is working on developing a research agenda related to university-industry relations.

Co-Director, San Francisco Cochrane Center (now San Francisco Branch, United States Cochrane Center). The Cochrane Collaboration is an international network of individuals who prepare, maintain, and disseminate systematic reviews and meta-analyses (Cochrane Reviews) of clinical interventions and other interventions to change health care delivery. The mission of the San Francisco Cochrane Center is to develop mechanisms for quality assurance of Cochrane Reviews and to develop a method for on-line continuous refereeing and updating of Cochrane Reviews.

Developed a problem-based learning module for teaching pharmacology to medical students, Field tested, Winter, 1992

UNIVERSITY AND PUBLIC SERVICE

University of Colorado Anschutz Medical Campus

2024	2 promotion committees (HSMP CoSPH), 2 search committees for faculty (CBH), 2 search committees for staff
2022-now	Member, Institutional Conflict of Interest Committee
2022	Member, Search Committee, Director of Arts and Humanities in Health Care Program
2022-now	Member, promotion committee

University of Sydney

2016-2018	Theme leader, Health Services and Patient Safety, Faculty of Pharmacy
2016-2019	Member, Faculty of Pharmacy Research Committee

- 2015-2019 Chair, Clinical Appointment Committee, Faculty of Pharmacy
- 2015-2019 Member, Pharmacy SEG (executive committee)
- 2015 Member, Industrial Engagement and Commercialisation Working Group
- 2014-now Member, Charles Perkins Centre Executive Committee
- 2014-now Chair, Charles Perkins Centre Engagement with Industry Committee
- 2014-now Staff Search and Promotion Committees, Faculty of Pharmacy

UCSF

University Service

(*1/2002-9/30/2002 Sabbatical) and (*9/2009 – 3/2010 on sabbatical) and left UCSF in 2014

University-wide

- 2013 – now Member, Task force on Research and Training Collaborations with UEH, University of California Haiti Initiative
- 2007 – 2008 Academic Senate Task Force on University Vendor Relations
- 2007 Academic Senate Task Force on Open Access Publication
- 2003-2006 Task Force on Institutional Conflict of Interest in Research Policy
- 2000-2004 University's Systemwide Library and Scholarly Information Advisory Committee
Member of Research Advisory Committee for SLASIAC project on journal conversion from print to electronic form

Campus-Wide

- 2014 Member, Committee to investigate faculty misconduct
- 2013 Member, Presidential Chair Award Committee
- 2011 Member, Office of Sponsored Research Advisory Board
- 2011, 2013 Member, Academic Senate Distinction in Mentoring Award Selection Committee
- 2011 Member, Search Committee for Director, Institute for Global Health, UCSF
- 2009-2014 Member, RAP grant review committee, Health Policy Section
- 2009-2014 Member, UCSF Ethics and Compliance Board (renamed Ethics Steering Committee in 2011)
- 2008 Member, Stewardship Review Committee for Department Chair

- 2008 Member, UCSF Health Care Vendor Relations Policy Development Committee
- 2007 Chair, Ad Hoc committee to review UCSF Affiliation agreement
- 2007 Member, UCSF Strategic Planning Design Team B: Research Directions
- 2007 Member, CTSI Community Engagement Program (CEP), Member Re-AIM Steering Group
- 2006-2008 Oversight Advisory Committee for OSR IT Systems Gap Analysis
- 2005-2006 Chancellor's Council
- 2005-2009 Committee on Research (Academic Senate Committee)
- 2005-2010 UCSF Strategic Planning Board member
- 2004-2005 Chancellor's Advisory Council. Faculty Representative, School of Pharmacy
- 2004 Served on one ad hoc Committees on Academic Promotion (CAP Committees)
- 2003-2004 Academic Senate Task Force on Conflicts of Interest and Research
- 2003 Served on one ad hoc Committees on Academic Promotion (CAP Committees)
- 2002-2005 Academic Planning and Budget (Vice Chair, Academic Senate Standing Committee)
- 1999-2010 Chair, Chancellor's Advisory Panel on Conflicts of Interest (formerly Chancellor's Advisory Panel on Relationships with Industry)
- 1999-2001 Chair, Committee on Academic Freedom (Academic Senate Standing Committee)
- 1999-2001 Committee on Equal Opportunity (Academic Senate)
- 1999 Task Force on UCSF School of Health
- 1999 Task Force on Climate for Women at UCSF
- 1999 Served on four ad hoc Committees on Academic Promotion (CAP Committees)
- 1999 UCSF Code of Conduct ad hoc Work Group
- 1999 Served on one ad hoc Committee on Academic Promotion (CAP Committees)
- 1998 Served on two ad hoc Committees on Academic Promotion Committees, Chaired one
- 1998 Member, Academic Senate Task Force for Review of Academic Senate Mission and Operations
- 1997-1999 Vice Chair, Committee on Academic Freedom (Academic Senate Standing Committee)
- 1997-1999 Vice Chair, Chancellor's Advisory Panel on Relationships with Industry

- 1996-2010 Chancellor's Advisory Panel on Relationships with Industry
- 1996 – 1999 Teaching and Instruction Committee, Medical Information Science Graduate Program
- 1996-1998 Executive Committee, Medical Information Science Graduate Program
- 1989–1994 UCSF/SFUSD Science Education Partnership Steering Committee

School of Medicine

- 2009-now Member, Harold S. Luft Award for Mentoring in Health Services and Health Policy Research Selection Committee
- 2005-2009 Member, Tobacco Control Policy Fellowship Admissions Committee
- 2001-2005 Chair, Tobacco Control Policy Fellowship Admissions Committee
- 2000-2004 Compensation Plan Committee
Space Policy Committee
- 1998-2008 Teaching Committee, Institute for Health Policy Studies
- 1997 - 2008 Faculty Advisory Committee, Institute for Health Policy Studies
- 1992 - 1996 Publications Review Committee, Institute for Health Policy Studies
- 1992 Computer Committee, Institute for Health Policy Studies
- 1992 – 1993 Executive Committee, Institute for Health Policy Studies
- 1991 – 2008 Health Policy Fellowship Admissions Committee, Institute for Health Policy Studies
- 1991 Academic Advisor to Postdoctoral Fellows, Institute for Health Policy Studies
- 1990 - 2010 Health Policy Fellowship Committee, Institute for Health Policy Studies

School of Pharmacy

- 2009-2013 Chair, judging for Department of Clinical Pharmacy Spring Research Seminar
- 2007 Co-Chair, Health Policy and Management Pathway for 6 months
- 2005 Chair, Search Committee for Chair of Department of Clinical Pharmacy
- 2003-2005 Educational Policy Committee
- 2003 Search Committee member, Assistant/Associate Professor of Pharmacy, Department of Clinical Pharmacy
- 2002 Search Committee member, Assistant/Associate Professor of Pharmacy, Department of Clinical Pharmacy
- 2000-2001 Medical Information Sciences Graduate Program, Student Welfare

1999-2000	Chair, Faculty Council
1999	Gender Equity (ad hoc) Committee
1998	Faculty Search Committee (for Assistant / Associate Professor)
1996	Faculty Search Committee (for Assistant Professor in Residence)
1996-2000	Executive Committee (now Faculty Council)
1996-1988	Study Design Cluster Curriculum Committee (Chair)
1995-now	Health Policy and Management Pathway Curriculum Committee
1995	Task Force on Joint Pharm.D. / Public Health Degree Program
1995	Faculty Search Committee (for Assistant Clinical Professor)
1995-1998	Educational Policy Committee
1994-1995	Strategic Planning Teaching Committee
1992 – 1993	Advisory Board, Longs Drugs – University of California San Francisco Collaboration
1992 - 1993	Graduate Instruction and Research Committee

Community Service

2016-now	Speaker for consumer advocacy groups on how to identify bias in research
2015-now	Training workshops for journalists on how to identify conflicts of interest in research
2012	Panel Discussion Participant. “Does Corporate Funding Corrupt Science?” Wonderfest: The Bay Area Beacon of Science. Stanford University, Palo Alto (March 2)
2007	Judge for High School Students video contest for World No Tobacco Day. Torino, Italy (May 31)
2006	I was featured in two videos on evidence-based health care. One was produced by the Lesbian, Gay, Bisexual and Transgender Community Center of New York City and the other by an Australian video production team. Both videos have been widely distributed to consumers through organizations such as Consumers’ Union and the Cochrane Collaboration Consumer Network.
2000-now	I respond to requests for written and oral commentary on state and federal regulations and legislation on a regular basis; at least 3 times per year. For example, in 2005, I provided written and oral testimony on California AB71, Drug Safety Law and on the Federal Clinical Trials Registration Legislation. In 2007, I

provided background information for California AB2821, Pharmaceutical Gift Reporting Bill, and have been invited to provide testimony in 2008.

- 2003 Filmed for educational video on secondhand smoke produced by the California Department of Health Services. The video has been distributed to all health departments in the state and numerous departments outside the state.
- 2003 Member American Lung Association / Marin Tobacco Free Coalition.
- 1998-2001 SEEDS (Science and Environmental Education Development) Docent, Dixie School District, San Rafael, CA
- 1993-2000 Member of speaker pool for the Science Education Partnership Program, UCSF and the San Francisco Unified School District, topic: "Good Drugs, Bad Drugs."
- 1988–1996 Partner with high school teacher for the Science Education Partnership Program, UCSF and the San Francisco Unified School District. Also participant in other partnership activities such as judge for lesson plan contest, training pharmacy students in the "Pharmacists Against Drug Abuse Program"
- 1988-89 Member of the community advisory board for the County Community Consortium, San Francisco – a group of community physicians doing clinical trials of AIDS therapies

PUBLICATIONS

List of Published Work in MyBibliography:

https://www.ncbi.nlm.nih.gov/myncbi/1b_NrarM_rIYvJ/bibliography/public/

Peer-reviewed Journal Articles

1. Morahan H, Hancock N, **Bero L**, Rooney K. Experiences of early career researchers: Influences on the design and reporting of animal experiments, and the practical and emotional support needed to enhance best practice methods. *Lab Anim*. 2024 Aug 5;236772241242850.
2. Qureshi R, Naaman K, Quan NG, Mayo-Wilson E, Page MJ, Cornelius V, Chou R, Boutron I, Golder S, **Bero L**, Doshi P, Vassar M, Meursinge Reynders R, Li T. Development and Evaluation of a Framework for Identifying and Addressing Spin for Harms in Systematic Reviews of Interventions. *Ann Intern Med*. 2024 Aug;177(8):1089-1098.
3. Grundy Q, Held F, MacIsaac M, Baugh CM, Campbell EG, **Bero L**. Quantifying Industry Spending on Promotional Events Using Open Payments Data. *JAMA Health Forum*. 2024 Jun 7;5(6):e241581.
4. McCambridge J, Kypri K, Boehnke JR, **Bero L**, Bendtsen M. Randomised study of the effects of sense of entitlement and conflict of interest contrarianism on researcher decision-making to work with the alcohol industry. *BMC Public Health*. 2024 Jun 24;24(1):1680.
5. Kanukula R, McKenzie JE, **Bero L**, Dai Z, McDonald S, Kroeger CM, Korevaar E, Forbes A, Page MJ. Investigation of bias due to selective inclusion of study effect estimates in meta-analyses of nutrition research. *Res Synth Methods*. 2024 Jul;15(4):524-542.
6. Toews I, Anglemeyer A, Nyirenda JL, Alsaïd D, Balduzzi S, Grummich K, Schwingshackl L, **Bero L**. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study. *Cochrane Database Syst Rev*. 2024 Jan 4;1(1):MR000034.
7. Blaxall M, Richardson R, Schoonees A, Metzendorf MI, Durão S, Naude C, **Bero L**, Farquhar C. Obesity intervention evidence synthesis: Where are the gaps and which should we address first? *Obes Rev*. 2024 Apr;25(4):e13685.
8. Traeger AC, **Bero LA**. Corporate Influences on Science and Health-the Case of Spinal Cord Stimulation. *JAMA Intern Med*. 2024 Feb 1;184(2):129-130.
9. Legg, T, **Bero L**, Lewandowsky S. The UK public's trust in tobacco industry involvement in science – an experimental survey. *Frontiers in Communication*. 9: 2024.
10. Page MJ, Sterne JAC, Boutron I, Hróbjartsson A, Kirkham JJ, Li T, Lundh A, Mayo-Wilson E, McKenzie JE, Stewart LA, Sutton AJ, **Bero L**, Dunn AG, Dwan K, Elbers RG, Kanukula R, Meerpohl JJ, Turner EH, Higgins JPT. ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis. *BMJ*. 2023 Nov 20;383:e076754.
11. Grundy Q, Held F, Hart D, Baugh CM, Ladd E, Campbell E, **Bero L**. Characteristics of Advanced Practice Nurses Receiving Top Industry Payments and Their Practice Settings: a Cross-sectional Study. *J Gen Intern Med*. 2024 May;39(7):1142-1148.

12. **Bero L**, Lawrence R, Oberste JP, Li T, Leslie L, Rittiphairoj T, Piper C, Wang GS, Brooks-Russell A, Yim TW, Tung G, Samet JM. Health Effects of High-Concentration Cannabis Products: Scoping Review and Evidence Map. *Am J Public Health*. 2023 Dec;113(12):1332-1342.
13. Langford AV, **Bero L**, Lin CC, Blyth FM, Doctor JN, Holliday S, Jeon YH, Moullin JC, Murnion B, Nielsen S, Penm J, Reeve E, Reid S, Wale J, Osman R, Gnjjidic D, Schneider CR. Context matters: using an Evidence to Decision (EtD) framework to develop and encourage uptake of opioid deprescribing guideline recommendations at the point-of-care. *J Clin Epidemiol*. 2024 Jan;165:111204.
14. Chiu K, Thow AM, **Bero L**. Understanding the Dynamics of More Restrictive Medicines Policy: A Case Study of Codeine Up-Scheduling in Australia. *Int J Health Policy Manag*. 2023;12:6872.
15. Langford AV, Lin CC, **Bero L**, Blyth FM, Doctor J, Holliday S, Jeon YH, Moullin J, Murnion B, Nielsen S, Osman R, Penm J, Reeve E, Reid S, Wale J, Schneider CR, Gnjjidic D. Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. *Med J Aust*. 2023 Jul 17;219(2):80-89.
16. Ong YK, Double KL, **Bero L**, Diong J. Responsible research practices could be more strongly endorsed by Australian university codes of research conduct. *Res Integr Peer Rev*. 2023 Jun 6;8(1):5.
17. Gaber N, **Bero L**, Woodruff TJ. The Devil they Knew: Chemical Documents Analysis of Industry Influence on PFAS Science. *Ann Glob Health*. 2023 Jun 1;89(1):37.
18. Pokorny AMJ, **Bero LA**, Fox P, Karikios DJ, McEwin EJ, Moynihan R, Mintzes B. Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study. *BMJ Open*. 2023 May 26;13(5):e065719.
19. Parker L, **Bero L**. Reducing commercial influence over guidelines won't fix poverty but is still worth striving for. *BMJ*. 2023 Mar 3;380:478.
20. Langford AV, Schneider CR, Lin CC, **Bero L**, Collins JC, Suckling B, Gnjjidic D. Patient-targeted interventions for opioid deprescribing: An overview of systematic reviews. *Basic Clin Pharmacol Toxicol*. 2023 Dec;133(6):623-639.
21. Grundy Q, Huyer LD, Parker L, **Bero L**. Branded Care: The Policy Implications of Pharmaceutical Industry-Funded Nursing Care Related to Specialty Medicines. *Policy Polit Nurs Pract*. 2023 Feb;24(1):67-75.
22. Joosse IR, Tordrup D, **Bero L**, Mantel-Teeuwisse AK, van den Ham HA. A critical review of methodologies used in pharmaceutical pricing policy analyses. *Health Policy*. 2023 Aug;134:104576.
23. **Bero L**, Lawrence R, Oberste JP, Li T, Leslie L, Rittiphairoj T, Piper C, Wang GS, Brooks-Russell A, Yim TW, Tung G, Samet JM. Health effects of high-concentration cannabis products: Scoping review and evidence map. *Am J Public Health*. 2023 Dec;113(12):1332-1342. doi:10.2105/AJPH.2023.307414.PMID: 37939329 Review.
24. Grundy, Q., Held, F., Hart, D., Baugh, C.M., Ladd, E., Campbell, E., & **Bero, L**. Characteristics of advanced practice nurses receiving top industry payments and their practice settings: A cross-sectional study. *J General Internal Medicine*. 2023; DOI: 10.1007/s11606-023-08508-6
25. Langford AV, **Bero L**, Christine Lin CW, Blyth FM, Doctor JN, Holliday S, Jeon YH, Moullin JC, Murnion B, Nielsen S, Penm J, Reeve E, Reid S, Wale J, Osman R, Gnjjidic D, Schneider CR.

- Context matters: Using an evidence to Decision (EtD) framework to develop and encourage uptake of opioid deprescribing guideline recommendations at point-of-care. *J Clin Epidemiol*. 2023 Nov 4:S0895-4356(23)00280-9.
26. Gaber N, **Bero L**, Woodruff TJ. The Devil they Knew: Chemical Documents Analysis of Industry Influence on PFAS Science. *Annals of Global Health*. 2023; 89(1): 37, 1-17.
 27. Parker L and **Bero L**. Managing risk from conflicts of interest in guideline development committees. *BMJ*. 2022; 379:e072252.
 28. Diong J, Kroeger CM, Reynolds KJ, Barnett A, **Bero LA**. Strengthening the incentives for responsible research practices in Australian health and medical research funding. *Res Integr Peer Rev* **6**, 11 (2021).
 29. Langford AV, Schneider CR, Lin CWC, **Bero L**, Collins JC, Suckling B et al. Patient-targeted interventions for opioid deprescribing. An overview of systematic reviews. *Basic and Clinical Pharmacology and Toxicology*.
 30. Chiu K, Thow AM, **Bero L**. Understanding the dynamics of more restrictive medicines policy: a case study of codeine up-scheduling in Australia. *International Journal of Health Policy and Management*. 12 (1), 1-11.
 31. Grundy, Q., Huyer, L. D., Parker, L., & **Bero, L.** (2022). Branded Care: The Policy Implications of Pharmaceutical Industry-Funded Nursing Care Related to Specialty Medicines. *Policy, Politics, & Nursing Practice*.
 32. Parker L, Boughton S, Lawrence R, **Bero L**. Experts identified warning signs of fraudulent research: a qualitative study to inform a screening tool. *J Clin Epidemiol*. 151:1-17; 2022
 33. Pega F, Momen NC, Gagliardi D, **Bero LA**, Boccuni F, Chartres N, Descatha A, Dzhambov AM, Godderis L, Loney T, Mandrioli D. Assessing the quality of evidence in studies estimating prevalence of exposure to occupational risk factors: The QoE-SPEO approach applied in the systematic reviews from the WHO/ILO Joint Estimates of the Work-related burden of disease and Injury. *Environment international*. 2022 Mar 1;161:107136.
 34. Pega F, Momen NC, **Bero L**, Whaley P. Towards a framework for systematic reviews of the prevalence of exposure to environmental and occupational risk factors. *Environmental Health*. 2022 Dec;21(1):1-7.
 35. Joosse IR, Tordrup D, **Bero L**, Mantel-Teeuwisse AK, van den Ham HA. A critical review of methodologies used in pharmaceutical pricing policy analyses. *Health Policy*. 2022 Mar 13.
 36. Pokorny AM, Fabbri A, **Bero LA**, Moynihan R, Mintzes BJ. Interactions with the pharmaceutical industry and the practice, knowledge and beliefs of medical oncologists and clinical haematologists: a systematic review. *British Journal of Cancer*. 2022 Jan;126(1):144-61.
 37. Korevaar E, Karahalios A, Turner SL, Forbes AB, Taljaard M, Cheng AC, Grimshaw JM, **Bero L**, McKenzie JE. Methodological systematic review recommends improvements to conduct and reporting when meta-analysing interrupted time series studies. *Journal of Clinical Epidemiology*. 2022 Jan 16.
 38. Morrow RL, Mintzes B, Souverein PC, Hallgreen CE, Ahmed B, Roughead EE, De Bruin ML, Kristiansen SB, Lexchin J, Kemp-Casey A, Sketris I, Mangin D, Pearson S-A, Puil L, Lopert R,

- Bero L**, Gnjidic D, Sarpatwari A, Dormuth C. Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. *Drug Safety*. 2022 Apr 19:1-6.
39. Chiu K, Thow AM, **Bero L**. The tension between national consistency and jurisdictional professional expansion: The case of pharmacist-administered vaccinations. *Research in Social and Administrative Pharmacy*. 2022 May 2.
40. Chiu K, Thow AM, **Bero L**. “Never waste a good crisis”: Opportunities and constraints from the COVID-19 pandemic on pharmacists’ scope of practice. *Research in Social and Administrative Pharmacy*. 2022 Apr 6.
41. Hilton Boon M, Burns J, Craig P, Griebler U, Heise TL, Vittal Katikireddi S, Rehfuess E, Shepperd S, Thomson H, **Bero L**. Value and Challenges of Using Observational Studies in Systematic Reviews of Public Health Interventions. *American Journal of Public Health*. 2022 Apr;112(4):548-52.
42. Morrow RL, Mintzes B, Souverein PC, De Bruin ML, Roughead EE, Lexchin J, Kemp-Casey A, Puil L, Sketris I, Mangin D, Hallgreen CE, Pearson S-A, Lopert R, **Bero L**, Oforo-Aseno R, Gnjidic D, Sarpatwari A, Perry L, Dormuth C. Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. *BMJ quality & safety*. 2022 Mar 1;31(3):179-90.
43. Kanukula R, McKenzie JE, **Bero L**, Dai Z, McDonald S, Kroeger CM, Korevaar E, Page MJ. Methods used to select results to include in meta-analyses of nutrition research: A meta-research study. *Journal of Clinical Epidemiology*. 2022 Feb 1;142:171-83.
44. Baram L, Dai Z, McDonald S, **Bero LA**. Disclosure of funding sources and conflicts of interest in evidence underpinning vitamin D and calcium recommendations in bone health guidelines. *Public Health Nutrition*. 2022 Jan 24:1-8.
45. Pokorny AM, Moynihan R, Fox P, Karikios DJ, **Bero LA**, Mintzes BJ. Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. *JCO Oncology Practice*. 2022 Mar:OP-21.
46. Mialon M, Bertscher A, **Bero L**, Vandevijvere S. Methods for evaluating efforts made by governments to prevent and mitigate corporate influence and conflicts of interest in public health policy. *HRB Open Research*. 2022 May 23;5:41.
47. Fabbri A, Nejstgaard CH, Grundy Q, **Bero L**, Dunn AG, Mohammad A, Mintzes B. Association between conflicts of interest and authors’ positions on harms of varenicline: a cross-sectional analysis. *Journal of general internal medicine*. 2022 Feb;37(2):290-7.
48. Neumann, I., Schünemann, H. J., **Bero, L.**, Cooke, G., Magrini, N., & Moja, L. (2021). Global access to affordable direct oral anticoagulants. *Bulletin of the World Health Organization*, 99(9), 653.
49. Langford, A. V., Gnjidic, D., Lin, C. W. C., **Bero, L.**, Blyth, F., Penm, J., & Schneider, C. R. (2021). “The lesser of two evils”: a framework analysis of consumers' perspectives on opioid deprescribing and the development of opioid deprescribing guidelines. *Pain*, 162(11), 2686-2692.
50. Parker, L., Grundy, Q., Fabbri, A., Mintzes, B., & **Bero, L.** (2021). ‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. *BMJ open*, 11(2), e045140.

51. Diong, J., Kroeger, C. M., Reynolds, K. J., Barnett, A., & **Bero, L. A.** (2021). Strengthening the incentives for responsible research practices in Australian health and medical research funding. *Research integrity and peer review*, 6(1), 1-7.
52. Dai, Z., Kroeger, C., McDonald, S., & **Bero, L.** (2021). What Contributes to the Variation of Dairy Recommendations in Global Food-Based Dietary Guidelines. *Current Developments in Nutrition*, 5(Supplement_2), 1264-1264.
53. Mialon, M., Vandevijvere, S., Carriedo, A., **Bero, L.**, Gomes, F., Petticrew, M., ... & Sacks, G. (2021). Mechanisms for addressing the influence of corporations on public health. *European Journal of Public Health*, 31(Supplement_3), ckab164-090.
54. **Bero L**, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, Grundy Q, Parker L, Boughton SL, Kirkham JJ, Featherstone R. Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. *BMJ Open* 2021;11:e051821.
55. Dai Z, McKenzie JE, McDonald S, Baram L, Page MJ, Allman-Farinelli M, Raubenheimer D, **Bero LA**. Assessment of the Methods Used to Develop Vitamin D and Calcium Recommendations—A Systematic Review of Bone Health Guidelines. *Nutrients* 2021, 13, 2423.
56. Kanukula R, McKenzie J, **Bero L**, Dai Z, McDonald S, Kroeger C, Korevaar E, Page M. Methods used to select results to include in meta-analyses of nutrition research: a meta-research study. *Journal of Clinical Epidemiology*. (2021).
57. Helfer B, Leonardi-Bee J, Mundell A, Parr C, Ierodiakonou D, Garcia-Larsen V, Kroeger C, Dai Z, Man A, Jobson J, Dewji F, Kunc M, **Bero L**, Boyle RJ. Conduct and reporting of formula milk trials: systematic review. *BMJ*. 2021;375:n2202.
58. Karanges, E. A., Nangla, C., Parker, L., Fabbri, A., Farquhar, C., **Bero, L.** Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study. *BMJ Open*. 2021 11: p. e049710-e049710
59. Soskolne CL, Kramer S, Ramos-Bonilla JP, Mandrioli D, Sass J, Gochfeld M, Cranor CF, Advani S, **Bero LA**. Toolkit for detecting misused epidemiological methods. *Environ Health*. 2021 Aug 19;20(1):90.
60. Chartres N, Fabbri A, McDonald S, Dion J, McKenzie J, **Bero L**. Association of food industry ties with findings of studies examining the effect of dairy food intake on cardiovascular disease and mortality: systematic review and meta-analysis. *BMJ Open* 2020;10:e039036.
61. Anglemyer_A, Moore_THM, Parker_L, Chambers_T, Grady_A, Chiu_K, Parry_M, Wilczynska_M, Flemyng_E, **Bero_L**. Digital contact tracing technologies in epidemics: a rapid review. *Cochrane Database of Systematic Reviews* 2020, Issue 8. Art. No.: CD013699.
62. Nejstgaard CH, **Bero L**, Hróbjartsson A, Jørgensen AW, Jørgensen KJ, Le M, Lundh A. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: Systematic review. *BMJ* .2020; 371:m4234.

63. Parker L, Bennett A, Mintzes B, Grundy Q, Fabbri A, Karanges EA, **Bero L**. 'There are ways ... drug companies will get into DTC decisions'- How Australian Drug and Therapeutics Committees address pharmaceutical industry influence. *Br J Clin Pharmacol*. 2020 Oct 31.
64. Moynihan R, Albarqouni L, Nangla C, Dunn A, Lexchin J, **Bero L**. Financial ties between leaders of influential US professional medical associations and industry: a cross-sectional study. *BMJ*. 2020. 369:m1505.
65. Turner K, Carboni-Jimenez A, Benea C, Elder K, Levis B, Borugg J, Roseman M, **Bero L**, Lexchin J, Turner EH, Benedetti A, Thombs BD. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. *BMJ Open*. 2020;10:e035633.
66. Moynihan R, Fabbri A, Parker L, **Bero L**. Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare. *BMJ Open*. 2020. 10:e034195.
67. Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, Korevaar E, Cheng AC, **Bero L**, McKenzie JE. Creating effective interrupted time series graphs: Review and recommendations. *Research Synthesis Methods*. 2020. 1-12.
68. Grundy Q, Dunn AG, **Bero L**. Improving researchers' conflict of interest declarations. *BMJ* 2020. 368:m422.
69. Grundy Q, Mazzaello S, **Bero L**. A comparison of policy provisions for managing "financial" and "non-financial" interests across health-related research organizations: A qualitative content analysis. *Accountability in Research*. 2020.
70. Langford AV, Gnjjidic D, Lin CC, **Bero L**, Penm J, Blyth FM, Schneider CR. Challenges of opioid deprescribing and factors to be considered in the development of opioid deprescribing guidelines: a qualitative analysis. *BMJ Qual Saf*. 2021. 30(2) 133-140. doi: 10.1136/bmjqs-2020-010881.
71. Pokorny AMJ, **Bero LA**, Moynihan R, Mintzes BJ. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly-available disclosures. *Intern Med J*. 2021 Aug 3.
72. Taylor KW, Wang Z, Walker VR, Rooney AA, **Bero LA**. Using interactive data visualization to facilitate user selection and comparison of risk of bias tools for observational studies of exposures. *Environ Int*. 2020 Sep;142:105806.
73. Mialon M, Vandevijvere S, Carriedo-Lutzenkirchen, **Bero L**, Gomes F, Pettigrew M, McKee M, Stuckler D, Sacks G. Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review. *BMJ Open*. 2020. 10:e034082.
74. Dai Z, Kroeger CM, Lawrence M, Scrinis G, **Bero L**. Comparison of methodological quality between the 2007 and 2019 Canadian dietary guidelines. *Public Health Nutr*. 2020 Nov;23(16):2879-2885.
75. Benea C, Turner KA, Roseman M, **Bero L**, Lexchin J, Turner E, Thombs B. Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. *Syst Rev* 2020; 9:77.
76. Karanges E, Ting N, Parker L, Fabbri A, **Bero L**. Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes. *Australian Journal of General Practice*. 2020; 49:3.

77. Turner S, Karahalios A, Forbes A, Taljaard M, Grimshaw J, Cheng A, **Bero L**, McKenzie J. Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: A review. *J Clin Epidemiol.* 2020;122: 1-11
78. Grundy Q, Mayes C, Holloway K, Mazzarello S, Thombs B, **Bero L**. Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine. *J Clin Epidemiol.* 2020; 120: 1-7.
79. Moynihan R, **Bero L**, Hill S, Johansson M, Lexchin J, Macdonald H, Mintzes B, Pearson C, Rodwin M, Stavdal A, Stegenga J, Thombs B, Thornton H, Vandvik PO, Wieseler B, Godlee F. Pathways to independence: towards producing and using trustworthy evidence. *BMJ* 2019; 367.
80. **Bero L**, Chiu K, Grundy Q. The SSSPIN study – spin in studies of spin: meta-research analysis. *BMJ* (Christmas Issue) 2019; 367: l6202.
81. Parker L, Fabbri A, Grundy Q, Mintzes B, **Bero L**. “Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study. *BMJ* 2019;367:l6694.
82. Chartres N, Grundy Q, Parker L, **Bero L**. “It’s not smooth sailing”: Bridging the gap between methods and content expertise in public health guideline development. *Int J Health Pol Management.* 2020.
83. Behdarvand B, Karanges EA, **Bero L**. Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study. *BMJ Open.* 2019;9:e030253.
84. Grundy Q, Chiu K, **Bero L**. Commercialization of user data by developers of medicines-related apps: A content analysis. *J Gen Int Med.* 2019, 1-9.
85. Ding D, Nguyen B, Gebel K, Bauman A, **Bero L**. Duplicate and salami publication: A prevalence study of journal policies. *Int J Epidemiol.* 2020 1-8.
86. Wang Z, Grundy Q, Parker L, **Bero L**. Health promoter, advocate, legitimiser – the many roles of WHO guidelines: a qualitative study. *Health Res Policy Sys.* 2019; 17:96.
87. Pega F, van Deventer E, Paulo MS, Woodruff T, Modenese A, Sgargi D, Loney T, Pachito D, Tenkate T, Descatha A, Ujita Y, Torreao D, Backes C, **Bero L**, Norris S, Godderis L, Mandrioli D. RoB-SPEO: A tool for assessing risk of bias in studies estimating the prevalence of exposure to occupational risk factors developed by the WHO/ILO Work-Related Burden of Disease and Injury Study. *Env International.* 2020; 135: 105039.
88. Karanges E A, Grundy Q, **Bero L**. Understanding the nature and extent of pharmaceutical industry payments to nonphysician clinicians. *JAMA Int Med.* 2019.
89. Grundy Q, Chiu K, Held F, Continella A, **Bero L**, Holz R. Data sharing practices of medicines-related apps and the mobile ecosystem: traffic, content and network analysis. *BMJ.* 2019; 364:l92.
90. Chartres N, Fabbri A, McDonald S, Turton J, Allman-Farinelli M, McKenzie J, **Bero L**. Association of industry ties with outcomes of studies examining the effect of wholegrain foods on cardiovascular disease and mortality: systematic review and meta-analysis. *BMJ Open.* 2019;9:e022912.

91. McDonald S, Fabbri, Parker L, Williams J, **Bero L**. Medical donations are not always free: an assessment of compliance of medicine and medical device donations with World Health Organization Guidelines (2009-2017). *Int Health*. 2019.
92. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, **Bero L**. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. *BMJ Open*. 2019;0:e025864.
93. van der Eijk Y, **Bero LA**, Malone RE. Philip Morris International-funded ‘Foundation for a Smoke-Free World’: analysing its claims of independence. *Tobacco Control*. Published Online First: 21 September 2018.
94. **Bero L**, Chartres N, Diong J, Fabbri A, Ghersi D, Lam J, Lau A, McDonald S, Mintzes B, Sutton P, Turton J, Woodruff T. The Risk of Bias in Observational Studies of Exposures (ROBINS-E) Tool: Concerns arising from application to observational studies of exposures. *Syst Rev*. 2018 7:242
95. Chartres, N, **Bero L** and Norris, S. A review of methods used for hazard identification and risk assessment of environmental hazards. *Environment International*. 2019; 123:231-239
96. Parker L, **Bero L**, Gillies D, Raven M, and Grundy Q. The “hot potato” of mental health app regulation: A critical case study of the Australian policy arena. *Int J Health Policy and Management*. 2019.
97. Parker L, Karanges E, and **Bero L**. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. *BMJ Open*. 2018;0:e024928.
98. Fabbri A, Holland TJ, **Bero L**. Food industry sponsorship of academic research: investigating commercial bias in the research agenda. *Public Health Nutrition*. 2018 21(18), 3422-3430.
99. Fabbri A, Lai A, Grundy Q, **Bero L**. The influence of industry sponsorship on the research agenda: a scoping review. *Am J Public Health*. 2018: e1-e8.
100. Parker L, Williams J, **Bero L**. Ethical drug marketing criteria for the 21st century. *BMJ*. 2018 Apr 30;361:k1809.
101. Parker L, Grundy Q, **Bero L**. Interpreting evidence in general practice: Bias and conflicts of interest. *Aust J Gen Pract*. 2018 Jun;47(6):337-340
102. Parker L, **Bero, L**. Gillies D, Raven M, Mintzes B, Jureidini J, Grundy Q. Mental Health Messages in Prominent Mental Health Apps. *Ann Fam Med*. 2018 Jul;16(4):338-342. (among the 20 most read articles published in Annals in 2018)
103. Rasmussen K, **Bero L**, Redberg R, Gotzsche P, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. *BMJ*. 2018; 363:k3654.
104. Rezende LFMd, Rey-López JP, Sá THd, Chartres N, Fabbri A, Powell L, Stamatakis E, **Bero L**. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. *PLoS Biol* 2018; 16(6): e2005761.
105. Grundy Q, Dunn AG, Bourgeois FT, Coiera E, **Bero L**. Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores. *JAMA*. 2018 Jan 23;319(4):408-409. doi: 10.1001/jama.2017.20738.

106. Wang Z, Norris SL, **Bero L**. The advantages and limitations of guideline adaptation frameworks. *Implement Sci*. 2018 May 29;13(1):72.
107. Mahmić-Kaknjo M, Jeličić-Kadić A, Utrobičić A, Chan K, **Bero L**, Marušić A. Essential medicines availability is still suboptimal in many countries: A scoping review. *J Clin Epidemiol* 2018; 98: 41-52.
108. Mintzes B, Swandari S, Fabbri A, Grundy Q, Moynihan R, **Bero L**. Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study. *BMJ Open*. 2018; 8(2) 8:e019027.
109. Blake P, Durao S, Naude C, **Bero L**. An analysis of methods used to synthesize evidence and grade recommendations in food-based dietary guidelines. *Nutrition Rev*. 2018; 76(4): 290-300.
110. Fabbri A, Chartres N, **Bero LA**. Study sponsorship and the nutrition research agenda: analysis of cohort studies examining the association between nutrition and obesity. *Public Health Nutrition*. 2017; 20(17): 3193-3199.
111. Grundy Q, Held F, **Bero L**. A Social Network Analysis of the Financial Links Backing Health and Fitness Apps. *American Journal of Public Health*. 2017.
112. Chiu K, Grundy Q, **Bero L** (2017) 'Spin' in published biomedical literature: A methodological systematic review. *PLoS Biol*. 15(9): e2002173.
113. Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E, **Bero L**. A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. *BMJ Open*. 2017;7:e016701.
114. Grundy Q, Held F, **Bero L**. Tracing the potential flow of consumer data: A network analysis of prominent health and fitness apps. *Journal of Med Internet Res*. 2017, 19:6.
115. Cosgrove I, Shaughnessy A, Peters S, Lexchin J, Bursztajn H and **Bero L**. Conflicts of interest and the presence of methodologists on guideline development panels: A cross-sectional study of clinical practice guidelines for major depressive disorder. *Psychother Psychosom*. 2017;86:168–170.
116. Apollonio D and **Bero L**. Interpretation and use of evidence in state policymaking: A qualitative analysis. *BMJ Open*. 2017, 7:e012738.
117. Walker J, Chaar B, Vera N, Pillai A, Lim J, **Bero L**, and Moles R. Medicine shortages in Fiji: A qualitative exploration of stakeholders' views. *PLoS ONE*. 2017; 12(6): e0178429.
118. Lundh A, Lexchin J, Mintzes B, Schroll JB, **Bero L**. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews*. 2017, Issue 2. Art. No.: MR000033.
119. Apollonio D, Philipps R and **Bero L**. Interventions for tobacco use cessation in people in treatment for or recovery from substance abuse. *Cochrane Database of Systematic Reviews*. 2016, Issue 11. Art. No.: CD010274.
120. Fabbri A, Chartres N, Scrinis G, **Bero LA**. Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity. *Public Health Nutrition*. 2016.

121. Chartres N, Fabbri A, **Bero LA**. Association of industry sponsorship with outcomes of nutrition studies: A systematic review and meta-analysis. *JAMA Int Med*. 2016.
122. Apollonio D, Wolfe N and **Bero LA**. Realist review of policy intervention studies aimed at reducing exposures to environmental hazards in the United States. *BMC Public Health*. 2016, 16: 822.
123. Mandrioli D, Kearns CE, **Bero LA** Relationship between Research Outcomes and Risk of Bias, Study Sponsorship, and Author Financial Conflicts of Interest in Reviews of the Effects of Artificially Sweetened Beverages on Weight Outcomes: A Systematic Review of Reviews. *PLoS ONE*. 2016, 11(9): e0162198.
124. Grundy, Q., Fabbri, A. Swandari, S., Mintzes, B. & **Bero, L.** (2016). The inclusion of nurses in pharmaceutical company-sponsored events: Guess who is also coming to dinner? *JAMA Internal Medicine*.
125. Morgan RL, Thayer KA, **Bero L**, Bruce N, Falck-Ytter Y, Ghersi D, Guyatt G, Hooijmans C, Langendam M, Mandrioli D, Mustafa RA, Rehfues EA, Rooney AA, Shea B, Silbergeld EK, Sutton P, Wolfe MS, Woodruff TJ, Verbeek JH, Holloway AC, Schunemann HS. GRADE: Assessing the quality of evidence in environmental and occupational health. *Environment International*. 2016; 92-93: 611-616.
126. Vandenberg L, Ågerstrand A, Beronius A, Beausoleild C, Bergman A, **Bero LA**, Bornehag C-G, Boyer CS, Cooper GS, Cotgreave I, Gee D, Grandjean P, Guyton K, Hass U; Jerry J Heindel; Susan Jobling; Karen A Kidd; Andreas Kortenkamp; Malcolm R Macleod; Olwenn V Martin; Ulf Norinder; Martin Scheringer; Kristina A Thayer; Jorma Toppari; Paul Whaley; Tracey J Woodruff; Christina Ruden. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals. *Environmental Health*. (2016) 15:74.
127. Grundy, Q, Wang Z, **Bero L**. Challenges in assessing mobile health app quality: A systematic review of prevalent and innovative methods. *American Journal of Preventive Medicine*. 2016.
128. Grundy Q, **Bero, L** and Malone, R. E. Marketing and the most trusted profession: The invisible interactions between registered nurses and industry. *Annals of Internal Medicine*. 2016.
129. Johnson PI, Koustas E, Vesterinen HM, Sutton P, Atchley DS, Kim AN, Campbell M, Donald JM, Sen S, **Bero L**, Zeise L, Woodruff TJ. Application of the Navigation Guide systematic review methodology to the evidence for developmental and reproductive toxicity of triclosan. *Environ Int*. 2016.
130. Wang Z, Norris SL, **Bero L**. Implementation plans included in World Health Organisation guidelines. *Implementation Science*. 2016, 11:76.
131. **Bero L**, Anglemeyer A, Vesterinen H and Krauth D. The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis. *Environ Int*. 2015.
132. Alexander PE, Gionfriddo MR, Li SA, **Bero L**, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, Schünemann HJ, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. *J Clin Epidemiol*. 2015; Sep 21.

133. Chang L, Dhruva SS, Chu J, **Bero LA**, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. *BMJ*. 2015; Jun 10;350:h2613.
134. Tran DN and **Bero L**. Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. *J Global Health*. 2015; 5 (1): e010406.
135. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, Barratt A, **Bero L** and McCaffery K. Public opinions about overdiagnosis: A national community survey. *PLoS One*. 2015; 10(5): e0125165.
136. Anglemeyer AT, Krauth D, **Bero L**. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: A meta-analysis. *BMC Medical Research Methodology*. 2015; 15: 12.
137. Chiu Y, **Bero L**, Hessol NA, Lexchin J, Harrington C. A literature review of clinical outcomes associated with antipsychotic medication use in North American Nursing home residents. *Health Policy*. 2015; Jun 119(6):802-13.
138. Siler K, Lee K and **Bero L**. Measuring the effectiveness of scientific gatekeeping. *Proc Nat Acad Sci*. 2015 Jan 13; 112 (2) 360-365.
139. Odierna DH and **Bero LA**. Retaining participants in outpatient and community-based health studies: Researchers and participants in their own words. *Sage Open*, 2014; 4 (4): 1-11.
140. Abdel-Sattar M, Krauth D, Anglemeyer A, and **Bero L**. The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: A meta-analysis. *Evidence-based Preclinical Medicine*. 2014; 1 (1) 11–20.
141. Alexander, PE, Brito, JP, Neuman, I, Gionfriddo MR, **Bero, L**, Djulbegovic, B, Stoltzfus, R, Montori, VM, Norris S, Schünemann H and Guyatt, G. World Health Organization strong recommendations based on low quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. *J Clin Epidemiol*, 2014; Dec 19.
142. Schroll JB, Abdel-Sattar M, and **Bero L**. FDA reports provide more data but are more difficult to use than EMA reports. *J Clin Epidemiol*. 2015 Jan;68(1):102-7
143. Apollonio DE, Glantz SA, **Bero LA**. Term limits and the tobacco industry. *Soc Sci Med*. 2014 Mar;104:1-5.
144. Forsyth S, Odierna DH, Krauth D and **Bero L**. Conflicts of interest and critiques of the use of systematic reviews in policymaking: An analysis of opinion articles. *Systematic Reviews*. Nov 2014 18;3(1):122.
145. Mahady SE, Schlub T, **Bero L**, Moher D, Tovey D, George J, Craig JC. Side effects are incompletely reported among systematic reviews in gastroenterology. *J Clin Epidemiol*. 2014 Aug 11.
146. Anglemeyer A, Horvath HT, and **Bero L**. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. *Cochrane Database of Systematic Reviews*. 2014, Issue 4.

147. Krauth, D, Anglemeyer, A, Philipps, R and **Bero, L**. Non-industry sponsored preclinical studies yield greater efficacy estimates than industry sponsored studies: A meta-analysis. *PLoS Biology*. 2014 12(1): e1001770.
148. Coralic Z, Kanzaria HK, **Bero LA**, Stein JC. Staff perceptions of an on-site clinical pharmacist program in an academic emergency department after one year. *West J Emerg Med*. 2014 Mar;15(2):205-10.
149. Alexander, PE, **Bero, L**, Montori, VM, Brito, JP, Stoltzfus, R, Djulbegovic, B, Neuman, Rave, S and Guyatt, G. World Health Organization recommendations are often strong based on low confidence in effect estimates. *J Clin Epidemiol*. 2014 Jan 3.
150. Grundy Q, **Bero L**, Malone R. Interactions between Non-Physician Clinicians and Industry: A Systematic Review. *PLoS Med*. 2013; 10(11): e1001561.
151. Chahal, HS, St. Fort, N, and **Bero, L**. Availability, prices and affordability of essential medicines in Haiti. *J Global Health*. 2013; 3(2).
152. Krauth, D, Woodruff, T and **Bero, L**. Instruments for assessing risk of bias and other methodological criteria of published animal studies: A systematic review. *Environmental Health Perspectives*. 2013; 121:985-992.
153. Moynihan, RN, Cooke, GPE, Doust, JA, **Bero, L**, Hill, S, and Glasziou, PP. Expanding disease definitions in guidelines and expert panel ties to industry: A cross-sectional study of common conditions in the United States. *PLoS Med*. 2013; 10(8): e1001500.
154. Wolfe, N, Gotzsche, PC and **Bero, L**. Strategies for obtaining unpublished drug trial data: A qualitative interview study. *Systematic Reviews*. 2013; 2:31.
155. Schroll, JB, **Bero, L**, Gotzsche, P. Searching for unpublished data for Cochrane reviews: Cross sectional study. *BMJ*. 2013; 346:f2231.
156. Conway, J, **Bero, L**, Ondari, C and Wasan, KM. Review of Quality of Pediatric Medicines in Developing Countries. *J Pharmaceutical Sciences*. 2013.
157. Nguyen, NY, and **Bero, L**. Medicaid drug selection committees inadequately manage conflicts of interest. *JAMA Internal Medicine*. 2013.
158. Odierna, D, Forsyth, S, White, J and **Bero, L**. The cycle of bias in health research: A framework and toolbox for critical appraisal training. *Accountability in Research*. 2013; 20:2, 127-141.
159. Pande, S, Hiller, JE, Nkansah, N and **Bero, L**. The effect of pharmacist-provided non-dispensing services on patient outcomes, health services utilization and costs in low-and middle-income countries. *Cochrane Database of Syst Rev*. 2013, Issue 2.
160. **Bero, L**, Hill, S, Habicht, J, Mathiesen, and Starkopf, J. The updated clinical guideline development process in Estonia: An efficient method for developing evidence-based guidelines. *J Clin Epidemiol*. 2013; 66: 132-139.
161. Lundh, A, Sismondo, S, Lexchin, J, Busuioac, OA, and **Bero, L**. Industry sponsorship and research outcome. *Cochrane Database of Syst Rev*. 2012;12:MR000033.

162. Odierna, D, White, J, Forsyth, S and **Bero, L**. Critical appraisal training increases understanding and confidence and enhances the use of evidence in diverse categories of learners. *Health Expectations*. 2012 Dec 16.
163. Taba, P, Rosenthal, M, Habicht, J, Tarien, H, Mathiesen, M, Hill, S and **Bero, L**. Barriers and facilitators to implementation of clinical practice guidelines: A cross-sectional survey. *BMC Health Services Research*. 2012; 12:455.
164. Roseman, M, Turner, EH, Lexchin, J, Coyne, JC, **Bero, LA**, Thombs, BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 2012;345:e5155.
165. Hill, S, Yang, A and **Bero, L**. Priority medicines for maternal and child health: A global survey of national Essential Medicines Lists. *PLoS One*. 2012; 7(5):e38055.
166. Malone, R, Grundy, Q and **Bero, L**. Tobacco industry denormalization as a tobacco control interventions: A review. *Tobacco Control*. 2012; 21: 162-170.
167. Norris, SL, Burda, BU, Holmer, HK, Ogden, LA, Fu, R, **Bero, L**, Schunemann, H and Deyo, R. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. *J Clin Epidemiol*. 2012 Jul; 65(7):725-33.
168. Anson, A, Ramay, B, Ruiz de Esparza, A, and **Bero, L**. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. *Globalization and Health*. 2012, 8:22-32.
169. Hart, B, Lundh, A and **Bero, L**. The effect of reporting bias on meta-analyses of drug trials: Re-analysis of meta-analyses. *BMJ*. 2012;344:d7202.
170. Walleser, S, Hill, S and **Bero, L**. Characteristics and reporting of cluster-randomized trials in children: reporting needs improvement. *J. Clin. Epidemiol*. 2011; 64: 1331-1340.
171. Millar, T, Wong, S, Odierna, DH and **Bero, L**. Applying the Essential Medicines concept to United States preferred drug lists. *American Journal of Public Health*. 2011;101: 1444–1448.
172. Woodruff, TJ, Sutton, P and The Navigation Guide Work Group*. An Evidence-Based Medicine Methodology To Bridge The Gap Between Clinical And Environmental Health Sciences. *Health Affairs*. 2011; 30 (5):931-937. (*I am a member of the Navigation Guide Work Group)
173. Dhruva, S, **Bero, L**, and Redberg, R. Gender bias in studies for FDA premarket approval of cardiovascular devices. *Circulation Cardiovasc Qual Outcomes*. 2011; 4: 165-171.
174. Roseman, M, Milete, K, **Bero, LA**, Coyne, JC, Lexchin, J, Turner, EH and Thombs, BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *Journal of the American Medical Association*. 2011; 305(10): 1008-1017.
175. Krleža-Jerić K, Lemmens T, Reveiz L, Cuervo LG, **Bero LA**. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. *Rev Panam Salud Publica*. 2011; 30(1):87-96
176. Chen, C, Dhruva, S, **Bero, L** and Redberg, R. Inclusion of training patients in Food and Drug Administration pre- market approval cardiovascular device studies. *Arch Intern Med*. 2011; 171: 534-539.

177. Ridge, AL, **Bero, LA** and Hill, SR. Identifying barriers to the availability and use of magnesium sulphate injection in resource poor countries: A case study in Zambia. *BMC Health Services Research*. 2010. 10: 340-349.
178. **Bero, L**, Carson, B, Moller, H, Hill, S. To give is better than to receive: compliance with WHO guidelines for drug donations during 2000–2008. *Bulletin of the World Health Organization*. 2010.
179. Cataldo, JK, **Bero, L** and Malone, RE. ‘A delicate diplomatic situation’: Tobacco industry efforts to gain control of the Framingham study. *J Clin Epidemiol*. 2010; 63: 841-853.
180. Robertson, J, Walkom, E, Moynihan, R, **Bero, L** and Henry, D. Pharmaceutical industry funding of educational events for pharmacists in Australia: An analysis of data from the first 6 months of a mandatory disclosure programme. *Int J Pharmacy Practice*. 2010; 18: 88-92.
181. White, J, **Bero, LA**. Corporate manipulation of research: Strategies are similar across five industries. *Stanford Law & Policy Review*. 2010; 21(1):105-134.
182. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, **Bero L**. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. *Cochrane Database Syst Rev*. 2010; (7):CD000336.
183. Smith, M, **Bero, LA**, and Carber, L. Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. *Chiropractic & Osteopathy*. 2010; 18: 30.
184. Montini, T, George, A, Martin-Mollard, M, and **Bero, L**. The role of public participation in public health initiatives: An analysis of WHO’s framework convention on tobacco control. *Global Public Health*. 2010; 5: 48-61.
185. Dhruva, S, **Bero, L**, Redberg, R. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. *Journal of the American Medical Association*. 2009; 302(24): 2679-2685.
186. Vedula, S, **Bero, L**, Scherer, R, Dickersin, K. Outcome reporting in industry-sponsored trials of Gabapentin for off-label use. *New England Journal of Medicine*. 2009; 361(20): 1963-1971.
187. Robertson, J, Moynihan, R, Walkom, E, **Bero, L** and Henry, D. Mandatory disclosure of pharmaceutical industry funded events for health professionals. *PLoS Medicine*. 2009; 6(11).
188. Rasmussen, N, Lee, K, **Bero, L**. Association of trial registration with the results and conclusions of published trails of new oncology drugs. *Trials*. 2009; 10: 116.
189. Cook, D, Gurugubelli, RK, and **Bero, L**. Risk Management Policy and Black Box Warnings at the US Food and Drug Administration. *Drug Safety*. 2009; 32(11): 1057-1066.
190. Apollonio, D, and **Bero, L**. Evidence and argument in policymaking: Development of workplace smoking legislation. *BioMed Central Public Health*. 2009.
191. Cook, D, and **Bero, L**. The politics of smoking in federal buildings: An executive order case study. *American Journal of Public Health*. 2009.
192. Cook, D, Boyd, E, Grossmann, C, and **Bero, L**. Journalists and conflicts of interest in science: Beliefs and practices. *Ethics in Science and Environmental Politics*. 2009.

193. Odierna, D and **Bero, L.** Systematic reviews reveal an unrepresentative evidence base for the development of drug formularies for poor and nonwhite populations. *J Clin Epidemiol.* 2009.
194. Rattinger, G and **Bero, L.** Factors associated with results and conclusions of trials of thiazolidinediones. *PLoS One.* 2009; 4: (6).
195. White, J, Bandura, A and **Bero, L.** Moral disengagement in the corporate world. *Accountability in Research.* 2009; 16: (1) 41-74.
196. Kummerfeldt, C, Barnoya, J, and **Bero, L.** Philip Morris involvement in the development of an air quality laboratory in El Salvador. *Tobacco Control.* 2009; 18 (1).
197. Nkansah, N, Nguyen, T, Iraninezhad, H and **Bero, L.** Randomized trials assessing calcium supplementation in healthy children: Relationship between industry sponsorship and study outcomes. *Public Health Nutrition.* 2009.
198. Rising, K, Bacchetti, P, and **Bero, L.** Reporting bias in drug trials submitted to the Food and Drug Administration: A review of publication and presentation. *PLoS Medicine.* 2008; 5 (11) e217.
199. Montini, T, and **Bero, L.** Implementation of a workplace smoking ban in bars: The limits of local discretion. *BMC Public Health.* 2008, 8:402.
200. Jewell, C, and **Bero, L.** Developing good taste in evidence: Facilitators and hindrances to evidence-informed health policy making in state government. *The Milbank Quarterly.* 2008 Jun; 86(2):177-208.
201. Cook, DM, Boyd EA, Grossman C, and **Bero, L.** Reporting science and conflicts of interest in the lay press. *PLOS [Public Library of Science].* 2007; 2: e1266.
202. Yank, V, Rennie, D, and **Bero, L.** Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort. *BMJ.* 2007; 335: 1202-1205.
203. Prochaska, J, Hall, S, and **Bero, L.** Tobacco use among individuals with schizophrenia: What role has the tobacco industry played? *Schizophrenia Bulletin.* 2008.
204. Apollonio, DE, P Lopipero, and **Bero, L.** Participation and argument in legislative debate on statewide smoking restrictions. *Health Research and Policy Systems.* 2007; 5: 1-11.
205. Boyd, E, and **Bero, L.** An analysis of university conflict of interest committee decisions. *Science and Engineering Ethics.* 2007; 13: 415-435.
206. Lopipero, P, Apollonio, DE, and **Bero, L.** Interest groups, lobbying and deception: The tobacco industry and airline smoking. *Political Science Quarterly.* Winter 2007-08; 122: 635-656.
207. White, J, Parascandola, M, and **Bero, L.** Tobacco industry research and protection of human subjects: A case study of R.J. Reynolds. *Nicotine and Tobacco Research.* 2007; 9: 1213-1225.
208. **Bero, L.**, Oostvogel, F, Bacchetti, P, and Lee, K. Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. *PLOS Medicine.* 2007; 4: 6: e184.

209. Steinman, MA, Harper, GM, Chren, MM, Landefeld, CS, and **Bero, L.** Characteristics and impact of drug detailing for Gabapentin. *PLOS Medicine*. 2007; 4: 4: e134.
210. Apollonio, D, and **Bero, L.** Creating industry front groups: The tobacco industry and “Get Government Off Our Back.” *American Journal of Public Health*. 2007; 97: 419-427.
211. Jewell C, and **Bero, L.** Public participation and claims making: Evidence utilization and divergent policy frames in California’s ergonomics rulemaking. *Journal of Public Administration Research and Theory*. December 2006.
212. Boyd, EA, and **Bero, LA.** Improving the use of research evidence in guideline development: 4. Managing conflicts of interests. *Health Research Policy and Systems*. 2006; 4: 16.
213. Cook, D, and **Bero, L.** Identifying carcinogens: The tobacco industry and regulatory politics in the United States. *Int J of Health Services*. 2006; 36: 747-766.
214. Nguyen, NT, Cook, DM, and **Bero, LA.** The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the counter status: A comparative case study. *Clinical Therapeutics*. 2006; 28: 1231-1243.
215. **Bero, LA.** Evaluating systematic reviews and meta-analyses. *Journal of Law & Policy*. 2006; 14: 569-593.
216. Lopipero, P, and **Bero, L.** Tobacco interests or the public interest: Twenty years of industry strategies to undermine airline smoking restrictions. *Tobacco Control*. 2006; 15: 323-332.
217. Steinman, MA, **Bero, LA,** Chren, M-M, and Landefeld, S. The promotion of Gabapentin: An analysis of internal industry documents. *Annals of Internal Medicine*. 2006; 145: 284-293.
218. Lee, K, Boyd, E, Holroyd-Leduc, J, Bacchetti, P, and **Bero, L.** Predictors of publication: Characteristics of submitted manuscripts associated with acceptance at major biomedical journals. *Medical Journal of Australia*. 2006; 184: 621-626.
219. Hong, M-K, and **Bero, L.** Tobacco industry sponsorship of a book and conflict of interest. *Addiction*. 2006; 101:1202-1211.
220. Glaser, B, and **Bero, L.** Attitudes of academic and clinical researchers toward financial ties in research: A systematic review. *Science and Engineering Ethics*. 2005; 11: 553-573.
221. Cook, D, Tong, E K, Glantz, S A, and **Bero, L.** The power of paperwork: How Philip Morris neutralized the medical code for secondhand smoke. *Health Affairs*. 2005; 24: 994-1004.
222. Baba, A, Cook, D, McGarity, T, and **Bero, L.** Legislating “Sound Science”: Role of the tobacco industry. *American Journal of Public Health*. 2005; S1: S20-S27.
223. Devine, EB, Beney, J, and **Bero, LA.** Equity, accountability, transparency: Implementation of the contributorship concept in a multi-site study. *Am J Pharmaceutical Education*. 2005; 69: 455-459.
224. **Bero, LA.** Tobacco industry manipulation of research. *Public Health Reports*. 2005; 120: 200-208.

225. **Bero, LA**, Glantz, S, and Hong, M-K. The limits of competing interest disclosures. *Tobacco Control*. 2005; 14: 118-126.
226. Dunsby, J, and **Bero, LA**. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes. *Tobacco Control*. 2004; 13: 362-369.
227. Lipton, S, Boyd, E, and **Bero, LA**. Conflicts of interest in research: Policies, processes and attitudes. *Accountability in Research*. 2004; 11: 83-102.
228. Boyd, EA, Lipton, S, and **Bero, L**. Implementation of financial disclosure policies to manage conflicts of interest. *Health Affairs*. 2004; 23: 206-214.
229. White, J, and **Bero, L**. Public health under attack: The American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. *American Journal of Public Health*. 2004; 94: 240-250.
230. Finley, PR, Rens, HR, Pont, JT, Gess, SL, Louie, CL, Bull, SA, Lee, JY, and **Bero, LA**. Impact of a collaborative care model on depression in a primary care setting: A randomized controlled trial. *Pharmacotherapy*. 2003, 23: 1175-1185.
231. Boyd, E, Cho, M, and **Bero, L**. Financial conflict of interest policies in clinical research: Issues for clinical investigators. *Academic Medicine*. 2003; 78: 769-774.
232. Lexchin, J, **Bero, L**, Djulbegovic, B, and Clark, O. Pharmaceutical industry sponsorship and research outcome and quality: A systematic review. *British Medical Journal*. 2003; 326: 1167-1170.
233. Roth, A, Dunsby, J, and **Bero, L**. Framing processes in public commentary on U.S. federal tobacco control regulation. *Social Studies in Science*. 2003; 33: 7-44.
234. Bryan-Jones, K, and **Bero, L**. Tobacco industry efforts to defeat the occupational safety and health administration indoor air quality rule. *American Journal of Public Health*. 2003; 93: 585-592.
235. Grimshaw, J, McAuley, L, **Bero, L**, Grilli, R, Oxman, A, Ramsay, C, Vale, L, Zwarenstein, M. Systematic reviews of the effectiveness of quality improvement strategies and programs. *Quality and Safety in Health Care*. 2003; 12: 298-303.
236. **Bero, L**. Implications of the tobacco industry documents for public health and policy. *Ann. Rev. Public Health*. 2003; 24: 267-288.
237. Hong, M, and **Bero, L**. How the tobacco industry responded to an influential study of the health effects of secondhand smoke. *British Medical Journal*. 2002; 325: 1413-1416.
238. Montini, T, Mangurian, C, and **Bero, L**. Assessing the evidence submitted in the development of a workplace smoking regulation: The case of Maryland. *Public Health Reports*. 2002; 117: 291-298.
239. Shamasunder, B, and **Bero, L**. Financial ties and conflicts of interest between pharmaceutical and tobacco companies. *Journal of the American Medical Association*. 2002; 288: 738-744.

240. Finley, B, Rens, H, Pont, J, Gess, S, Louie, C, Bull, S, and **Bero, L**. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. *American Journal of Health-System Pharmacy*. 2002; 59: 1518-1526.
241. Beney, J, Devine, EB, Chow, V, Ignoffo, RJ, Mitsunaga, L, Shahkarami, M, McMillan, A, and **Bero, L**. Effect of telephone follow-up on the physical well-being dimension of quality of life in patients with cancer. *Pharmacotherapy*. 2002; 22: 1301-1311.
242. Mowatt, G, Shirran, L, Grimshaw, J, Rennie, D, Flanagan, A, Yank, V, MacLennan, G, Gotzsche, P, and **Bero, L**. Prevalence of honorary and ghost authorship in Cochrane Reviews. *Journal of the American Medical Association*. 2002; 287: 2769-2771.
243. Lee, K, Schotland, M, Bacchetti, P, and **Bero, L**. Association of journal quality indicators with methodological quality of clinical research articles. *Journal of the American Medical Association*. 2002; 287: 2805-2808.
244. Rochon, P, **Bero, L**, Bay, A, Gold, J, Dergal, J, Binns, M, Streiner, D, and Gurwitz, J. Comparison of review articles published in peer-reviewed and throwaway journals. *Journal of the American Medical Association*. 2002; 287: 2853-2856.
245. Malone, R, Wenger, L, and **Bero, L**. High school journalists' perspectives on tobacco. *Journal of Health Communications*. 2002; 7: 139-156.
246. Ober, M, Shohara, R, Rennie, D, Yank, V, and **Bero, L**. The criticism management system for the Cochrane Library. *Evaluation and the Health Professions*. 2002; 25: 98-115.
247. Schotland, M, and **Bero, L**. Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. *Risk Analysis*. 2002; 22: 131-140.
248. **Bero, LA**, Montini, T, Bryan-Jones, K, and Mangurian, C. Science in regulatory policy making: Case studies in the development of workplace smoking restrictions. *Tobacco Control*. 2001; 10: 329-336.
249. Shojania, K, and **Bero, L**. An efficient Medline search strategy for identifying systematic reviews of the literature. *Effective Clinical Practice*. 2001; 4: 157-162.
250. Montini, T, and **Bero, L**. Policy makers' perspectives on public health advocates' roles in regulation development. *Tobacco Control*. 2001; 10: 218-224.
251. Grimshaw, JM, Shirran, L, Thomas, R, Mowatt, G, Fraser, C, **Bero, L**, Grilli, R, Harvey, E, Oxman, A, and O'Brien, MA. Changing provider behavior: An overview of systematic reviews of interventions. *Medical Care*. 2001; 39: II2-II45.
252. Wenger, LD, Malone, RE, George, A, and **Bero, L**. Cigar magazines: Using tobacco to sell a lifestyle. *Tobacco Control*. 2001; 10: 279-284.
253. Wenger, L, Malone, R, and **Bero, L**. The cigar revival and the popular press: A content analysis 1987-1997. *American Journal of Public Health*. 2001; 91: 288-291.
254. Boyd, E, and **Bero, L**. Assessing faculty financial relationships with industry: A case study. *Journal of the American Medical Association*. 2000; 284: 2209-2214.

255. Moynihan, R, **Bero, L**, Ross-Degnan, D, Henry, D, Lee, K, Watkins, J, Mah, C, and Soumerai, S. Coverage by the news media of the benefits and risks of medications. *The New England Journal of Medicine*. 2000; 342: 1645-1650.
256. Malone, R, Boyd, E, and **Bero, L**. Science in the news: Journalists' constructions of passive smoking as a social problem. *Social Studies of Science*. 2000; 30: 713-735.
257. Mangurian, C, and **Bero, L**. Lessons learned from the tobacco industry's efforts to prevent the passage of a workplace smoking regulation. *American Journal of Public Health*. 2000; 90: 1926-1930.
258. Halladay, M, and **Bero, L**. Implementing evidence-based practice in health care. *Public Money and Management*. 2000; 20: 43-50.
259. Malone, R, and **Bero, L**. Cigars, youth and the internet link. *American Journal of Public Health*. 2000; 90: 790-792.
260. Kennedy, G, and **Bero, L**. Print media coverage of research on passive smoking. *Tobacco Control*. 1999; 8: 254-260.
261. Freemantle, N, Harvey, EL, Wolf, F, Grimshaw, JM, Grilli, R, and **Bero, LA**. Printed educational materials: Effects on professional practice and health care outcomes. *Cochrane Review*. 1999; Issue 2. Oxford: Update Software. (first published in 1994, removed in 2007 due to out of date).
262. **Bero, LA**, Mays, NB, Barjesteh, K, and Bond, C. Expanding the roles of outpatient pharmacists: Effects on health services utilisation, costs, and patient outcomes. *Cochrane Review*. 1999; Issue 2. Oxford: Update Software (first published in 1995).
263. Misakian, S, and **Bero, L**. Publication bias and research on passive smoking. *Journal of the American Medical Association*. 1998; 280 (13): 250-253.
264. Barnes, D, and **Bero, L**. Why review articles on the health effects of passive smoking reach different conclusions. *Journal of the American Medical Association*. 1998; 279: 1566-1570.
265. **Bero, L**, Grilli, R, Grimshaw, J, Harvey, E, Oxman, AD, and Thomson, MA on behalf of the Cochrane Effective Practice and Organization of Care Group. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. *British Medical Journal*. 1998; 317: 465-468.
266. **Bero, L**, and Jadad, A. How patients and policy makers can use systematic reviews for decision-making. *Annals of Internal Medicine*. 1997; 127: 37-42.
267. Barnes, D, and **Bero, L**. Scientific quality of original research articles on environmental tobacco smoke. *Tobacco Control*. 1997; 6: 19-26.
268. Stryer, D, and **Bero, L**. Characteristics of materials distributed by drug companies. *Journal of General Internal Medicine*. 1996; 11: 575-583.
269. Barnes, D, and **Bero, L**. Industry-funded research and conflict of interest: An analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. *Journal of Health Politics, Policy and Law*. 1996; 21 (3): 515-542.

270. **Bero, LA**, and Rennie, D. Influences on the quality of published drug studies. *International Journal of Technology Assessment in Health Care*. 1996; 12 (2): 209-237.
271. Phillips, KA, and **Bero, L**. Improving the use of information in medical effectiveness and quality research. *International Journal for Quality in Health Care*. 1996; 8 (1): 21-30.
272. Cho, M, and **Bero, L**. The quality of drug articles published in symposium proceedings. *Annals of Internal Medicine*. 1996; 124: 485-489.
273. De Vries, TPGM, Henning, RH, Hogerzeil, HV, Bapna, JS, **Bero, L**, Kafle, KK, Mabadeje, AFB, Santoso, B, and Smith, AJ. Impact of a short course in pharmacotherapy for undergraduate medical students: An international randomised controlled study. *Lancet*. 1995; 346: 1454-1457.
274. **Bero, LA**, Barnes, DE, Hanauer, P, Slade, J, and Glantz, SA. Lawyer control of the tobacco industry's external research program: The Brown and Williamson Documents. *Journal of the American Medical Association*. 1995; 274: 241-247.
275. Slade, J, **Bero, LA**, Hanauer, P, Barnes, DE, and Glantz, SA. Nicotine and addiction: The Brown and Williamson Documents. *Journal of the American Medical Association*. 1995; 274: 225-233.
276. Hanauer, P, Slade, J, Barnes, DE, **Bero, LA**, and Glantz, SA. Lawyer control of internal scientific research to protect against products liability lawsuits: The Brown and Williamson Documents. *Journal of the American Medical Association*. 1995; 274: 234-240.
277. Barnes, DE, Hanauer, P, Slade, J, **Bero, LA**, and Glantz, SA. Environmental tobacco smoke: The Brown and Williamson Documents. *Journal of the American Medical Association*. 1995; 274: 248-253.
278. Glantz, SA, Barnes, DE, **Bero, LA**, Hanauer, P, and Slade, J. Looking through a keyhole at the tobacco industry: The Brown and Williamson Documents. *Journal of the American Medical Association*. 1995; 274: 219-224.
279. Kearney, T, Olson, K, **Bero, LA**, Heard, S, and LaBlanc, P. The health care cost impact due to public usage of a Regional Poison Control Center in California. *Western Journal of Medicine*. 1995; 162: 499-504.
280. **Bero, L**, and Rennie, D. The Cochrane Collaboration: Preparing, maintaining, and disseminating systematic reviews of the effects of health care. *Journal of the American Medical Association*. 1995; 274: 1935-1938.
281. **Bero LA**, Glantz, SA, and Rennie, D. Publication bias and public health policy on environmental tobacco smoke. *Journal of the American Medical Association*. 1994; 272: 133-136.
282. Cho, MK, and **Bero, LA**. Instruments for assessing the quality of drug studies published in the medical literature. *Journal of the American Medical Association*. 1994; 272: 101-104.
283. Glantz, SA, and **Bero, LA**. Inappropriate and appropriate selection of "Peers" in grant review. *Journal of the American Medical Association*. 1994; 272: 114-116.
284. **Bero, L**, Galbraith, A, and Rennie, D. Sponsored symposia on environmental tobacco smoke. *Journal of the American Medical Association*. 1994; 271: 612-617.

285. **Bero, LA**, and Glantz, SA. Tobacco industry response to a risk assessment of environmental tobacco smoke. *Tobacco Control*. 1993; 2: 103-113.
286. **Bero, LA**, Galbraith, A, and Rennie, D. The publication of sponsored symposiums in medical journals. *New England Journal of Medicine*. 1992; 327: 1135-1140.
287. Lipton, HL, Bird, JA, **Bero, LA**, and McPhee, SJ. Assessing the appropriateness of physician prescribing for geriatric outpatients: Developing and testing of an instrument. *Journal of Pharmacy Technology*. 1992; 9: 107-113.
288. Lipton, HL, **Bero, LA**, Bird, JA, and McPhee, SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing: A randomized controlled trial. *Medical Care*. 1992; 30: 646-658.
289. **Bero, LA**, Lipton, HL, and Bird, JA. Characterization of geriatric drug-related hospital readmissions. *Medical Care*. 1991; 29: 989-1003.
290. **Bero, L.**, Roy, SA, and Lee, NM. Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody. *Molecular Pharmacology*. 1988; 34: 614-620.
291. **Bero, LA**, Lurie, SN, and Kuhn, CM. Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. *Developmental Brain Research*. 1987; 465: 189-196.
292. **Bero, LA**, and Kuhn, CM. Differential ontogeny of opioid, dopaminergic and serotonergic regulation of Prolactin Secretion. *The Journal of Pharmacology and Experimental Therapeutics*. 1987; 240: 825-830.
293. **Bero, LA**, and Kuhn, CM. Role of serotonin in opiate-induced prolactin secretion and antinociception in the developing rat. *The Journal of Pharmacology and Experimental Therapeutics*. 1987; 240: 831-836.
294. **Bero, LA**, and Kuhn, CM. Catecholaminergic regulation of opiate-stimulated growth hormone secretion in the developing rat. *The Journal of Pharmacology and Experimental Therapeutics*. 1986; 237: 137-142.
295. Nielsen, JA, Shannon, NJ, **Bero, LA**, and Moore, KE. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. *Pharmacology, Biochemistry and Behavior*. 1986; 24: 95-799.
296. Akera, T, Ng, YC, Shieh, IS, and **Bero, L.** Brody TM, & Braselton WC. Effects of potassium on the interaction between cardiac glycosides and Na,K-ATPase. *European Journal of Pharmacology*. 1985; 111: 147-158.
297. Kilts, CD, and **Bero, LA**. Quantitative determination of 5-hydroxytryptophan in dissected brain regions by on-line trace enrichment HPLC with electrochemical detection. *Life Sciences*. 1984; 35: 87-95.

Protocols

1. Wilkinson J, Heal C, Antoniou GA, Flemyng E, Alfirevic Z, Avenell A, Barbour G, Brown NJL, Carlisle J, Clarke M, Dicker P, Dumville JC, Grey A, Grohmann S, Gurrin L, Hayden JA, Heathers J, Hunter KE, Lasserson T, Lam E, Lensen S, Li T, Li W, Loder E, Lundh A, Meyerowitz-Katz G, Mol BW, O'Connell NE, Parker L, Redman BK, Seidler L, Sheldrick KA, Sydenham E, Torgerson D, van

- Wely M, Wang R, **Bero L**, Kirkham. JJProtocol for the development of a tool (INSPECT-SR) to identify problematic randomised controlled trials in systematic reviews of health interventions. *BMJ Open*. 2024 Mar 11;14(3):e084164.
2. Henke-Ciążyńska K, Fober I, Munblit D, Fabbri A, Grundy Q, **Bero L**, Boyle RJ, Helfer B. Cross-sectional examination of commercial milk formula industry funding of international, regional and national healthcare professional associations: protocol. *BMJ Open*. 2024 May 22;14(5):e083216.
 3. Korfitsen CB, Nejstgaard CH, Hróbjartsson A, Boutron I, Bero L, Lundh A. Peer reviewers' conflicts of interest in biomedical research: a scoping review protocol. Researchgate.net
 4. Bero, Lisa, Tianjing Li, Louis Leslie, Thanitsara Rittiphairoj, Christi Piper, Sam Wang, Ashley Brooks-Russell, Gregory Tung, Jon Samet. 2021. "Health Effects of High-potency Cannabis Products: A Scoping Review Protocol." OSF. December 11. doi: 10.17605/OSF.IO/WV7E9. URL: <https://osf.io/wv7e9>
 5. Chiu K, McDonald S, Legg T, Karanges EA, Bero L. [Policies affecting the supply and access of opioid analgesics: a scoping review protocol](#). JBI Evid Synth. 2020 May;18(5):1124-1134. doi: 10.11124/JBISIRIR-D-19-00095. PubMed PMID: 32813367.
 6. Korevaar E, Karahalios A, Forbes AB, Turner SL, McDonald S, Taljaard M, Grimshaw JM, Cheng AC, **Bero L**, McKenzie JE. [Methods used to meta-analyse results from interrupted time series studies: A methodological systematic review protocol](#). F1000Res. 2020;9:110. doi: 10.12688/f1000research.22226.1. eCollection 2020. PubMed PMID: 33163155; PubMed Central PMCID: PMC7607479.
 7. Page MJ, **Bero L**, Kroeger C, Dai Z, McDonald S, Forbes A, McKenzie JE. Investigation of risk of bias due to unreported and Selectively included results in meta-analyses of nutrition research: the ROBUST study protocol. *F1000 Research* 2019; 8:1760 <https://doi.org/10.12688/f1000research.20726.1>
 8. Mintzes B, Fabbri A, Grundy Q, Spurling GKP, Lexchin J, McKenzie JE, **Bero L**. Information and promotional strategies by pharmaceutical companies for clinicians. *Cochrane Database of Systematic Reviews* 2019, Issue 9. Art. No.: CD013423. DOI: 10.1002/14651858.CD013423.
 9. Dai Z, Kroeger C, McDonald S, Page M, McKenzie J, Allman-Farinelli M, Raubenheimer D, **Bero L**. Methodological quality of public health guideline recommendations on vitamin D and calcium intakes – a systematic review protocol. *BMJ Open*, 2019;9:e031840. doi: 10.1136/bmjopen-2019-031840.
 10. Trevena H, Reeve B, **Bero L**, Thow AM. Private food safety standards in the global food supply chain: a scoping review protocol. *JBI Database System Rev Implement Rep* 2019; 17(0)1-12. DOI: 10.11124/JBISIRIR-D-19-00006
 11. Turner S, Karahalios A, Forbes A, Taljaard M, Grimshaw J, Cheng A, **Bero L**, McKenzie J. Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: protocol for a review. *BMJ Open* 2019; 9:e024096. doi:10.1136/bmjopen-2018-024096

Preprints

1. Wilkinson J, Heal C, Antoniou GA, Flemyng E, Avenell A, Barbour V, Bordewijk EM, Brown NJL, Clarke M, Dumville J, Grohmann S, Gurrin LC, Hayden JA, Hunter KE, Lam E, Lasserson T, Li T, Lensen S, Liu J, Lundh A, Meyerowitz-Katz G, Mol BW, O'Connell NE, Parker L, Redman B, Seidler AL, Sheldrick K, Sydenham E, Dahly DL, van Wely M, **Bero L**, Kirkham JJ. A survey of experts to identify methods to detect problematic studies: Stage 1 of the INSPECT-SR Project. *medRxiv* [Preprint]. 2024 Mar 25:2024.03.18.24304479.
2. **Bero L**, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, Grundy Q, Parker L, Boughton SL, Kirkham JJ, Featherstone R (2021) Comparison of preprints and final journal publications from COVID-19 studies: Discrepancies in results reporting and spin in interpretation. *medRxiv*. <https://doi.org/10.1101/2021.04.12.21255329>.

Non-peer reviewed articles

1. Wang Z, Taylor K, Allman-Farinelli M, Armstrong B, Askie L, Ghersi D, McKenzie J, Norris S, Page M, Rooney A, Woodruff T, and **Bero L**. A systematic review: Tools for assessing methodological quality of human observational studies. Canberra, Australia: National Health and Medical Research Council, in press.
2. Montagu D, Anglemyer A, Tiwari M, Drasser K, Rutherford G, Horvath T, Kennedy G, **Bero L**, Shah N, and Kinlaw H. A comparison of health outcomes in public vs. private settings in low- and middle- income countries. iHEA pre-Congress Symposium on the Private Sector. Proceeding. 2011
3. Apollonio, DE, and **Bero, LA**. Industry front groups: A tobacco case study, *Journal fur Verbraucherschutz und Lebensmittelsicherheit* (Journal of Consumer Protection and Food Safety) 2007; 2: 1-8.
4. Michel MC, **Bero LA**, Bright T. Creating a text data-mining application for use in public health informatics. *Conf Proc IEEE Eng Med Biol Soc*. 2004; 5:3214-6.
5. Granados A, Jonsson E, Banta HD, **Bero L**, Bonair A, Cochet C, Freemantle N, Grilli R, Grimshaw J, Harvey E, Levi R, Marshall D, Oxman A, Pasart L, Räisänen V, Rius E, Espinas JA. EUR-ASSESS Project Subgroup Report on Dissemination and Impact. *Int J Technol Assess Health Care*. 1997; 13(2):220-86.

Editorials / Commentaries

1. **Bero L**. Stamp out fake clinical data by working together. *Nature*. 2022;601(7892):167-168.
2. **Bero, L.** (2021, August). ISEE principles for evidence synthesis and evaluation in environmental health. In *ISEE Conference Abstracts* (Vol. 2021, No. 1).
3. **Bero, L. A.**, & Parker, L. (2021). Risky business? Pharmaceutical industry sponsorship of health consumer groups. *AN INDEPENDENT REVIEW*, 74.
4. Boughton, S. L., Wilkinson, J., & **Bero, L.** (2021). When beauty is but skin deep: dealing with problematic studies in systematic reviews. *Cochrane Database of Systematic Reviews*, (5). <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000152/full>
5. Verbeek, J., Hoving, J., Boschman, J., Chong, L. Y., Livingstone-Banks, J., & **Bero, L.** (2021). Systematic Reviews Should Consider Effects From Both the Population and the Individual Perspective

6. **Bero, L.** Improving the quality of systematic reviews in public health: Introduction to the series. *Am J Pub Health.* 2020; 10:11, 1601-1602.
7. **Bero, L.** Producing independent, systematic review evidence: Cochrane's response to COVID-19. *Am J Pub Health.* 2020; 110:7, 952-953. <https://doi.org/10.2105/AJPH.2020.305734>
8. Moynihan R, Macdonald H, **Bero L**, Godlee F. [Commercial influence and covid-19.](#) *BMJ.* 2020 Jun 24;369:m2456. doi: 10.1136/bmj.m2456. PubMed PMID: 32580930.
9. Johansson M, **Bero L**, Bonfill X, Bruschetti M, Garner S, Glenton C, Harris R, Jørgensen KJ, Levinson W, Lotfi T, Montori V, Meng DM, Schünemann H, Vaz Carneiro A, Woloshin S, Moynihan R. [Cochrane Sustainable Healthcare: evidence for action on too much medicine.](#) *Cochrane Database Syst Rev.* 2019 Dec 6;12:ED000143. doi: 10.1002/14651858.ED000143. PubMed PMID: 31808554.
10. Samet J, Chiu W, Cogliano V, Jinot J, Kriebel D, Lunn R, Beland F, **Bero L**, Browne P, Fritschi L, Kanno J, Lachenmeier D, Lan Q, Lasfargues G, Le Curieux F, Peters S, Shubat P, Sone H, White M, Williamson J, Yakubovskaya M, Siemiatycki J, White P, Guyton K, Schubauer-Berigan M, Hall A, Grosse Y, Bouvard V, Bengrahim-Talla L, El Ghissassi F, Lauby-Secretan B, Armstrong B, Saracci R, Zavadil J, Straif K, Wild C. The IARC Monographs: Updated procedures for modern and transparent evidence synthesis in cancer hazard identification. *J Natl Cancer Inst* 2020; 112:1 doi: 10.1093/jnci/djz169
11. Moynihan R, Macdonald H, Heneghan C, **Bero L** and Godlee F. Commercial interests, transparency and independence: a call for submissions. *BMJ* 2019; 365:l1706 doi: 10.1136/bmj.l1706
12. Kearns CE, **Bero L.** Conflicts of interest between the sugary food and beverage industry and dental research organisations: time for reform. *The Lancet.* 2019 394: 194-196.
13. Baur X, Soskolne C, **Bero L.** How can the integrity of occupational and environmental health research be maintained in the presence of conflicting interests? *Env Health.*2019. 18:93. <https://doi.org/10.1186/s12940-019-0527-x>
14. **Bero L**, Norris SL, Lawrence MA. Making nutrition guidelines fit for purpose. *BMJ.* 2019 365: 11579 doi: 10.1136/bmj.l1579
15. **Bero L.** Ten tips for spotting industry involvement in science policy. *Tob Control.* 2018 Jun 25. pii: tobaccocontrol-2018-054386. doi: 10.1136/tobaccocontrol-2018-054386
16. **Bero L.** Meta-research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust. *PLoS Biol.* 2018 Apr 2;16(4):e2005972. doi: 10.1371/journal.pbio.2005972. eCollection 2018 Apr.
17. **Lisa A. Bero**, Quinn Grundy, Not All Influences on Science Are Conflicts of Interest, *American Journal of Public Health* 108, no. 5 (May 1, 2018): pp. 632-633. DOI: 10.2105/AJPH.2018.304334 PMID: [29617619](#)
18. **Bero L.** Getting the systematic review basics right helps clinical practice: 4 common pitfalls for systematic review authors to avoid. *Br J Sports Med.* 2017 Dec 7. pii: bjsports-2017-098239. doi: 10.1136/bjsports-2017-098239
19. **Bero L.** Developing reliable dietary guidelines. *BMJ* 2017;359:j4845

20. **Bero L.** Addressing bias and conflict of interest among biomedical researchers (Viewpoint). *JAMA*, 2017, 317 (17) 1723-1724.
21. Moynihan R and **Bero L.** Toward a healthier patient voice: More independence, less industry funding. *JAMA Int Med*, 2017, doi:10.1001/jamainternmed.2016.9179
22. Lundh A and **Bero L.** The ties that bind. *BMJ* 2017;356:j176 doi: 10.1136/bmj.j176
23. **Bero L** and Grundy Q. Why having a (non-financial) interest is not a conflict of interest (Perspective) *PLoS Biology*, *PLoS Biol*, 2017, 14(12): e2001221. doi:10.1371/journal.pbio.2001221
24. Lawrence, M, Naude, C, Armstrong, R, **Bero, L**, Covic, N, Durao, S, Ghersi, D, Macdonald, G, MacLehose, H, Margetts, B, Tovey, D, Volmink, J, Young, T. A call to action to reshape evidence synthesis and use for nutrition policy[editorial]. *Cochrane Database of Systematic Reviews* 2016;(11): [10.1002/14651858.ED000118](https://doi.org/10.1002/14651858.ED000118)
25. **Bero L.** Systematic Review: A method at risk for being corrupted. *Am J Public Health*, 2016; 107: 93-96. doi: 10.2105/AJPH.2016.303518
26. Norris S and **Bero L.** GRADE methods for guideline development: Time to evolve? *Annals of Int Med*, 2016, doi:10.7326/M16-1254
27. Elliott JH, Grimshaw J, Altman R, **Bero L**, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. *Nature*, 2015; Nov 5;527(7576):31-2. doi: 10.1038/527031a.
28. Tuller D and **Bero L.** Big tobacco and drug store chains: A long, cozy relationship. *JAMA Oncol*, 2015; Dec 1;1(9):1215-1216. doi: 10.1001/jamaoncol.2015.2621.
29. Hill SR, **Bero L**, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. *Bull World Health Organ*, 2015; Jan 1;93(1):4. doi: 10.2471/BLT.14.148924.
30. Schroll J, **Bero L.** Regulatory agencies hold the key to improving Cochrane Reviews of drugs[editorial]. *Cochrane Database of Systematic Reviews* 2015;(4): [10.1002/14651858.ED000098](https://doi.org/10.1002/14651858.ED000098)
31. **Bero L.** Why the Cochrane risk of bias tool should include funding source as a standard item[editorial]. *Cochrane Database of Systematic Reviews* 2013;(12): [10.1002/14651858.ED000075](https://doi.org/10.1002/14651858.ED000075)
32. **Bero, L.** Bias related to funding source in statin trials: The biases are clear if you know where to look. *BMJ* 2014;349:g5949. doi: <http://dx.doi.org/10.1136/bmj.g5949>
33. Fox, DM and **Bero L.** Systematic reviews: Perhaps “The answer to policymakers’ prayers”? *Env Health Persp.* 2014 122: A262-263 <http://dx.doi.org/10.1289/ehp.1408599>
34. **Bero, L.** What’s in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. *J Clin Epidemiol*, 2014 Nov;67(11):1239-41. doi: 10.1016/j.jclinepi.2014.06.015. Epub 2014 Aug 15. No abstract available. PMID: 25132356
35. Magrini N, Robertson J, de Joncheere K, **Bero L.** On WHO’s essential medicines process and transparency. *BMJ*. 2014 Sep 17;349:g5637. doi: 10.1136/bmj.g5637.

36. Formoso G, Marata AM, Magrini N, **Bero L**. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. *Cochrane Database Syst Rev*. 2014 Sep 15;9:ED000090. doi: 10.1002/14651858.ED000090.
37. Tovey D, Churchill R, **Bero L**. Evidence based medicine: looking forward and building on what we have learnt. *BMJ*. 2014 Jul 9;349:g4508. doi: 10.1136/bmj.g4508
38. Neltner TG, Alger HM, O'Reilly JT, Krinsky S, **Bero LA**, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. *JAMA Intern Med*. 2013 Dec 9-23;173(22):2032-6. doi: 10.1001/jamainternmed.2013.10559.
39. **Bero L**, Busuttill G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Smith R, Tovey D. Measuring the performance of The Cochrane Library. *Cochrane Database Syst Rev*. 2012 Nov 14;12:ED000048. doi: 10.1002/14651858.ED000048.
40. **Bero, L.** and Binder, L. The Cochrane Collaboration Review Prioritization Projects show that a variety of approaches successfully identify high priority topics. *J Clin Epidemiol*, Sep 5 2012. PMID: 22959591
41. Sutton P, Woodruff TJ, Vogel S, **Bero LA**. Conrad and Becker's "10 Criteria" Fall Short of Addressing Conflicts of Interest in Chemical Safety Studies. *Environ Health Perspect*. 2011 Dec 1; 119(12):a506-7.
42. **Bero L**, Ghersi D. Making systematic reviews global. *Cochrane Database Syst Rev*. 2011; (8):ED000020.
43. Smith R, Tovey D, **Bero L**, Busuttill G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Pais P. The cochrane library oversight committee. *Cochrane Database Syst Rev*. 2011; (8):ED000021.
44. **Bero, LA**. "Experimental" institutional models for corporate funding of academic research: Unknown effects on the research enterprise, *Journal Clin Epidemiol*, 2008; 61: 629-633.
45. Dickersin, K, Strauss, and **Bero, L**. Evidence based medicine: Increasing, not dictating, choice, *BMJ* 2007;334(suppl_1):s10 (6 January), doi:10.1136/bmj.39062.639444.94
46. **Bero L**. [Shall we ban industrial funds for research?]. *Epidemiol Prev*. 2007 Jul-Aug; 31(4):171-4
47. Lee, KP, and **Bero, LA**. Ethics: Increasing accountability. What authors, editors and reviewers should do to improve peer review. [An invited article written as part of the journal's web focus and debate on peer review] *Nature Online*, June 5, 2006.
48. **Bero, LA**. Clinical trial registration at Tobacco Control, [Editorial] *Tobacco Control*, 2006; 15: 417-418.
49. **Bero, LA**. Managing financial conflicts of interest in research [Invited review article], *J Am College of Dentists*, 2005; 72: 4-9.
50. Malone, RE, and **Bero, LA**. [Editorial] Chasing the dollar: Why scientists should decline tobacco industry funding, [Editorial] *Journal of Epidemiology and Community Health*, 2003; 57: 546-548.
51. **Bero, LA**. "Educational advertisements": I haven't seen one yet! [Editorial], *The Western Journal of Medicine*, 2001; 174 (6): 395.

52. Anderson J, Baum M, **Bero LA**, Chalmers I, Chapman S, Deary IJ, Ebrahim S, Evans M, Farrell M, Greaves D, Higginson I, Hippisley-Cox J, James B, McKenzie H, Macaulay AC, Rabow M, Smyth RL, Stores G, Wolpert L. Music to be born to, music to die to. BMJ. 2000 Dec 23-30; 321(7276):1577-9.
53. **Bero, LA**. Accepting commercial sponsorship: Disclosure helps but is not a panacea. [Editorial], British Medical Journal, 1999; 319: 653-654.
54. **Bero, LA**. Disclosure policies for gifts from industry to academic faculty [Editorial], Journal of the American Medical Association, 1998; 279: 1031-1032.
55. **Bero, LA**, Delamothe, T, Dixon, A, LaPorte, RE, Sekikawa, A, and Aaron, D. What might an online scientific paper look like in five years' time? [Editorial], British Medical Journal, 1997; 315: 1692-1696.
56. **Bero, LA**. More documentation of the futile search for a 'safer' cigarette: The Tobacco Products Research Trust 1982-1996 [Book Review], Tobacco Control, 1997 6: 250-251.
57. **Bero, LA**, and Rennie, D. The Cochrane Collaboration: Preparing, maintaining, and disseminating systematic reviews of the effects of health care [Editorial], Journal of the American Medical Association, 1995; 274: 1935-1938.
58. **Bero, LA**. Industry sponsorship of academic research [Editorial], in Outlook: Newsletter of the Society of Behavioral Medicine, 1995; Winter.
59. Rennie, DR, and **Bero, LA**. Throw it away, Sam. The controlled circulation journals [Editorial], Council of Biological Editors Views, 1990; 13: 31-35.

Play Review

1. **Bero, L**. Big Pharma (The Play) PLoS Biology, 2007. 5: 4, e104 doi:10.1371/journal.pbio.0050104

Letters to the Editor

1. Bero L, Hróbjartsson A, Grundy Q. Response to Soares et al (re publication of industry sponsored research) Eur J Clin Nutrition, in press.
2. Soskolne C, **Bero L**, Ruff K, Sass J, Advani S. Response to Acquavella J, Conflict of Interest: A Hazard for Epidemiology. Annals of Epidemiol, 2019. 36: 62-63.
3. **Bero L**, Grundy Q. Conflicts of Interest in Nutrition Research. JAMA. 2018 Jul 3;320(1):93-94. doi: 10.1001/jama.2018.5662.
4. Sutton P, Woodruff TJ, Vogel S, **Bero LA**. Conrad and Becker's "10 Criteria" Fall Short of Addressing Conflicts of Interest in Chemical Safety Studies. Environ Health Perspect. 2011 Dec 1; 119(12):a506-7.
5. Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, **Bero L**. CONSORT 2010. Lancet. 2010 Jul 24; 376(9737):229-30.

6. Schick, S, **Bero, LA**, and Cook, D. The tobacco industry and the data quality act [letter], Science, 2007; 317: 897-899.
7. Finley PR, **Bero L**. Clarification of study and citation. Arch Intern Med. 2007 Dec 10; 167(22):2531; author reply 2531-2.
8. **Bero, L**, Glantz, A, and Cummings, M. Tobacco industry misleading the public ... Again, British Medical Journal rapid response. May 23, 2003 (www.bmj.com)
9. Malone, RE, Wenger, L, and **Bero, LA**. Making the cigar news [research letter], Tobacco Control, 2000; 9: 435-437.
10. Stryer, DB, Lurie, P, and **Bero, LA**. Dear Doctor ... Regarding calcium channel blockers [letter], Journal of the American Medical Association, 1996; 275: 517-518.
11. Hornbein, T, **Bero, LA**, and Rennie, D. The publication of commercially supported supplements statement [letter], Anesthesia and Analgesia, 1995; 81: 887-888.
12. Stryer, DB, and **Bero, LA**. Drug promotion [letter], New England Journal of Medicine, 1995; 332 (15): 1032.

Chapters in Books

1. **Bero, L**. "Industry influence on research: A cycle of bias" in The Commercial Determinants of Health, Edited by Nason Maani*, Mark Petticrew*, and Sandro Galea. Oxford University Press. Oxford. 2022
2. **Bero, L**. "Tobacco industry manipulation of research," in Late Lessons from Early Warnings: Science, Precaution, Innovation. European Environmental Agency Report No 1/2013, Copenhagen (2013).
3. Van den Ham, R, **Bero, L** and Laing, R. "Selection of Essential Medicines," in The World Medicines Situation 2011, pp. 1-18, World Health Organization (2011).
4. Closing the gap between research and practice: An overview of systematic reviews of interventions to promote implementation of research findings by health care professionals. **Bero, L**, Freemantle, N, Grilli, R, Grimshaw, J, Harvey, E, Oxman, A, and Thomson, M. In Getting Research Findings into Practice, A Haines and A Donald, eds, London: BMJ Publishers (1998).
5. Long-term tranquiliser use: A health policy perspective. Lipton, HL, and **Bero, LA**. In Understanding Long-term Tranquiliser Use, Jonathan Gabe, Editor, London: Routledge Publishers (1991).
6. Neural adaptation in response to intrinsic and extrinsic factors: Role in drug abuse, Kuhn, CM, **Bero, LA**, and Ignar, DM. In Endocrine Consequences of Perinatal Opiate Exposure. NIDA Research Monograph. (1987).
7. Perinatal effects of drugs of abuse, Braude, MC, Szeto, JJ, Kuhn, CM, **Bero, LA**, Ignar, D, Field, E, Lurie, S, Chasnoff, IJ, Mendelson, JH, Zuckerman, B, Hingson, R, Frank, D, Parker, S, Vince, R, Kahyne, H, Morelock, S, Amaro, H, Kyei-Aboage, K, and Howard. J. Fed. Proceedings 46: 2446-2435 (1987).

Books, Monographs

1. Bero L. Industry influence on research: A cycle of bias in Commercial Determinants of Health, Ed Sandro Galea. Oxford University Press. 2022
2. J. White and **L Bero**. Chapter 8, Part 1: “Tobacco industry challenge to ASSIST: The tobacco industry’s response to ASSIST: An analysis of tobacco industry internal documents.” National Institute Monograph #16: ASSIST: Shaping the future of tobacco prevention and control. P. 309-349, 2005
3. Encyclopedia entry, Scribners, “Turning points in Science” series: “Tobacco in history and culture” Volume 2, Entry on “Tobacco Industry Science,” p. 625-626. 2005
4. People’s voices: Analysis of the public hearings on the framework convention on tobacco control, Montini, T, George, A, Martin, M, and **Bero L**. Report for the World Health Organization, 2002.
5. Methods for studying the effects of direct-to-consumer pharmaceutical advertising on health outcomes and health services utilization, **Bero, L**, and Lipton, S. Presented at a meeting on Assessing the Impact of Direct-to-Consumer Advertising on Health Care Use, Costs and Outcomes sponsored by the Assistant Secretary for Planning and Evaluation, Washington, D.C. May 31, 2001. www.hsrnet.com/ASPE/991/papers/Bero_preconf-draft.htm
6. Effective health care: Getting evidence into practice, February, 1999.

Bero, L. made a contribution to Effective Health Care.

7. Disclosure of tobacco industry documents, **Bero, L**, and Fox, B. Health Science Analysis Project, Policy Analysis Paper No. 1 (14 April 1998).
This paper was commissioned by the Advocacy Institute and Robert Wood Johnson Foundation as part of a series of analyses of Congressional Bills regarding a national tobacco settlement.
8. Report of the EURASSESS subgroup on dissemination and impact, Banta, D, **Bero, L**, Bonair, A, Cochet, C, Espinas, J, Freemantle, N, Grilli, R, Grimshaw, J, Harvey, E, Levi, R, Marshall, D, Oxman, A, Pazart, L, Rius, E, and Raisanen, V. The Swedish Council on Technology in Health Care: Stockholm. June, 1996.

Bero, L was sole author of the Executive Summary of the report and co-author of Chapter 2, The Executive Summary is circulated as a separate document.

9. The cigarette papers, Glantz, SA, J, Slade, **Bero, L**, Hanauer, P, and Barnes, D. Berkeley, Ca: UC Press, 1996.
10. Impact of a short course in Pharmacotherapy for undergraduate medical students: An international multicentre study, TPGM de Vries, Henning, RH, Hogerzeil, HV, Bapna, JS, **Bero, LA**, Kafle, KK, Mabadeje, AFB, Santoso, B, and Smith, AJ. Action Programme on Essential Drugs, World Health Organization, (WHO/DAP/95.1) 1995.
11. Model guide to good prescribing, TPGM de Vries, Henning, RH, Hogerzeil, HV, Bapna, JS, **Bero, LA**, Kafle, KK, Mabadeje, AFB, Santoso, B, and Smith, AJ. Action Programme on Essential Drugs, World Health Organization, 1995.
12. Sponsored symposia and their publication in medical journals. **Bero, LA**, Galbraith, A, and Rennie, D. Institute for Health Policy Studies Monograph Series, November, 1992.

Curriculum Vitae
Lisa Anne Bero

Dissertation

1. The interaction of opioid and serotonergic systems regulation prolactin secretion in the developing rat, Duke University (1987).